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Hay fever is typically poorly managed, particularly in adolescents, in whom it is 
responsible for considerable morbidity and impairment in educational performance. 
Evidence-based training of professionals has the potential to improve outcomes, but 
it can be expensive and so warrants formal evaluation. This trial sought to evaluate 
the effectiveness of a training intervention for primary care-based health care 
professionals on adolescent disease-specific quality of life. 
 
Methods 
A cluster randomised controlled trial was conducted in UK general practices. 
Practices were centrally randomised to a short, intensive training course on the 
evidence-based management of hay fever (intervention arm) or distribution of 
guidelines (control arm). The primary outcome measure was the change in the 
validated Rhinoconjunctivitis Quality of Life Questionnaire with Standardized 
Activities (RQLQ(S)) score in adolescents with hay fever between baseline and six 
weeks post-intervention (minimal clinically important difference = 0.5). Secondary 
outcome measures included health care professionals’ knowledge and confidence in 
managing hay fever, number of hay fever-related consultations, relevant treatments 
prescribed and symptom scores. Multi-level modelling using a random effects model 
was used to take account of between and within cluster variation, adjusting for strata, 






Thirty-eight general practices were randomised (20 in the intervention arm) and 
246/341 patients (50.2% male, mean age 15 years) were included in the primary 
outcome analysis. Health care professionals’ self-assessed knowledge and confidence 
improved (prescribing/recommending treatment mean score 95% CI 1.4, 2.8), and 
the training was perceived to be of value. This did not however result in clinically or 
statistically significant improvements in RQLQ(S): -0.15, 95% CI -0.52 to +0.21. 
There were no differences in consultation frequency (95% CI -0.02, +0.63), 




Although attendance on this short, intensive hay fever training course was associated 
with professionals’ increased self-assessed confidence and understanding of the 
clinical management of hay fever, this did not translate into improvements in 
disease-specific quality of life or reduction in rhinitis symptoms in adolescents with 
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Chapter 1 – Introduction 
This opening chapter introduces key concepts in relation to allergic disorders with 
particular reference to hay fever. The current definitions of allergic disorders and 
how these evolved over time are reviewed, moving on to discuss the epidemiology 
and disease burden associated with hay fever. Existing evidence-based treatment 
guidelines for primary care, shortcomings in the provision of care, and the need for 
educational interventions for primary-care based health professionals are considered 
in relation to the development of the intervention used in the cluster randomised 
controlled trial.   
1.1. Allergy 
The term allergy was introduced first proposed by Clemens von Pirquet in 1906 (von 
Pirquet 1906) and was generally understood to describe the concept of altered 
biological reactivity to an antigen, which he defined as a foreign substance which 
could be either protective (offering immunity) or allergenic (harmful) (Kay 2001). 
This term is however sometimes now used in a more restrictive sense so it is 
synonymous with IgE-mediated disorders, these including, for example, allergic 
rhinitis and subsets of asthma and anaphylaxis (Johansson et al. 2001).   
1.2. Early descriptions of hay fever 
Early references to clinical observations resembling modern day allergy appear as far 
back as the 2
nd
 century AD (Emanuel 1988), however no descriptions of hay fever-
like symptoms appear before about the 16
th
 century. Reference to ‘smelling roses and 
symptoms of headache, sneezing and troublesome itching of the nose’ dating from 
the middle of the 16
th
 century are described in a monograph entitled ‘Hayfever, its 
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etiology and treatment’ by Sir Morell Mackenzie in 1884. The expression ‘hayfever’ 
was coined in the 1800s by John Bostock, who in 1819 theorised that the symptoms 
were caused by the fumes and, therefore, heat from hay. In this classic description of 
himself, Bostock describes all the afflictions we recognise as symptoms of hay fever 
today:  
‘A general fullness is experienced in the head, and particularly about the fore part; 
to this succeeds irritation of the nose,  producing sneezing, which occurs in fits of 
extreme violence, coming on at uncertain intervals’. (Bostock 1819) 
It was 50 years later before the scientist Charles Blackley related his own symptoms 
to pollen by collecting and storing grass pollen until the winter months, when he 
inhaled the pollen and noted an acute reaction of streaming eyes, running nose and 
sneezing (Sheikh et al. 2013). In the 19
th
 century, hay fever became more common in 
Europe and North America, a rise which has been closely associated with post-
Industrial Revolution urbanisation, which brought about changes in agricultural 
practice, population movements and a very different way of life for much of the 
population (Emanuel 1988).   
1.3. Definitions and classification of rhinitis 
Allergic rhinitis has been defined as a symptomatic disorder of the nose induced by 
an IgE-mediated inflammation after allergen exposure of the membranes of the nose 
(Scadding et al. 2007). It is characterised clinically by symptoms such as 
rhinorrhoea, sneezing, nasal blockage and itching of the nose (Greiner et al. 2011) 
which are reversible, either spontaneously or with treatment; current definitions 
suggest that these symptoms need to occur during two or more consecutive days 
(Bousquet et al. 2008). Rhinitis can be classified into non-allergic and allergic; 
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allergic rhinitis can further be divided into intermittent or persistent (Bousquet, 
Khaltaev et al. 2008). There are several causes of non-infectious rhinitis and of these 





Table 1.1: Classification of rhinitis (from ARIA 2008 update (Bousquet, 
Khaltaev et al. 2008)) 
 
Classification Type/Cause 




Other infectious agents 
Occupational Intermittent  
Persistent 
Drug induced Aspirin 
Other medications 
Hormonal e.g. during pregnancy or menopause 









Allergic rhinitis was previously classified on the basis of time of exposure and 
duration of symptoms into seasonal or perennial (International Rhinitis Management 
Working Group 1994), depending on sensitisation to seasonal tree, grass and weed 
pollens and mould spores, or allergens which are present all year round such as house 
dust mites and animal dander. This classification system was thought unhelpful 
globally, as many countries do not have distinct seasons, pollens and moulds are 
perennial in some areas, and symptoms of perennial rhinitis may not be present all 
year round depending on allergen exposure. The classification system was therefore 
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revised in the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline 
(Bousquet, Khaltaev et al. 2008) to one based on the frequency and severity of 
symptoms and shown in Table 1.2.  
Table 1.2: Classification of allergic rhinitis according to ARIA (adapted from 
ARIA 2008 (Bousquet, Khaltaev et al. 2008)) 
 
Intermittent symptoms 
 Less than four days a week or 
 Less than four consecutive weeks  
Persistent symptoms 
 More than four days a week and 
 More than four consecutive 
weeks  
Mild 
 Normal sleep 
 Normal daily activities 
 Normal work and school 
 Symptoms present but not 
troublesome 
Moderate to severe (one or more 
present) 
 Sleep disturbance 
 Impairment of daily activity, 
leisure, sport 
 Impairment of school or work 
 Troublesome symptoms 
 
1.3.1. Nomenclature used in this thesis 
The terms seasonal and perennial cannot be used interchangeably with intermittent 
and persistent, as they do not represent the same stratum of disease (Bousquet, 
Khaltaev et al. 2008). However, in Western Europe, tree and grass pollens are the 
most important aeroallergens leading to allergic symptoms in the spring and summer 
and therefore the terms seasonal allergic rhinitis as well as intermittent rhinitis or 
even allergic rhinitis are commonly used in the literature. When reporting directly 
from the literature the term referred to by the authors will be used, however, for the 
purposes of the patients described in the trial reported in my thesis, the term hay 
fever will be used for intermittent allergic rhinitis as the seasonality is clear in the 
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United Kingdom (UK) (Scadding et al. 2008), with most general practitioners still 
using the code for seasonal allergic rhinitis/hay fever in patient electronic medical 
records for diagnosis (Hammersley et al. 2011). 
1.4. Biological mechanisms of allergic rhinitis 
Allergic rhinitis is a symptomatic disorder of the nose induced after allergen 
exposure, which results in immunoglobulin E (IgE)-mediated inflammation of the 
membranes lining the nose (World Health Organization Initiative et al. 2001). 
Coombs and Gell (1963) proposed a classification of four different reaction patterns 
for allergic reactions; allergic rhinitis is, using the classification system, a clinical 
example of Type 1 Immediate Hypersensitivity. Exposure to the allergen leads to 
cross-linking of membrane bound IgE on mast cells and/or basophils, which in turn 
causes a release of immediate mediators such as histamine and the formation of 
prostaglandins and leukotrienes and synthesis of cytokines, which further amplify the 
reaction (Roeken et al. 2003). The immediate response to mediator release will be 
nasal itching, sneezing, rhinorrhoea and congestion of the nose. When allergen levels 
are high or contact continues, a late phase response involving cellular inflammatory 
infiltrates such as eosinophils can lead to chronic ongoing rhinitis symptoms, such as 
nasal blockage and nasal hyper-reactivity (Scadding 2008). 
1.5. Prevalence of allergic diseases 
Allergy is one of the most common chronic diseases and affects up to 50% of the UK 
paediatric population at some point in their lives (Punekar et al. 2009). The world-
wide prevalence of respiratory allergies has dramatically increased in the past 50 
years (Asher et al. 2006; Bjorksten et al. 2008) and in the last decade food allergy 
has emerged as the second wave of the allergy epidemic (Prescott et al. 2011). 
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Atopic eczema/dermatitis is estimated to affect one in three children under 18 years, 
one in five with asthma and one in 10 with rhinitis (Punekar and Sheikh 2009). There 
is some evidence from time trend analysis of existing datasets and surveys that the 
prevalence of hay fever may be stabilising (Gupta et al. 2007). More recent evidence 
of atopic eczema/dermatitis incidence and prevalence showed no clear global trend; 
however, prevalence appears to be increasing in western Europe and parts of 
northern Europe, including the UK (Deckers et al. 2012). In addition to these high 
levels of individual disease prevalence, multiple allergic conditions often co-exist, 
figures of up to 16% of children under 18 years have been found to have more than 
one allergic disease (Punekar and Sheikh 2009; Punekar et al. 2009) which may 
partly be explained by the concept of the atopic march, which describes the 
progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis 
and asthma in children (Spergel et al. 2003).  
1.6. Epidemiology of allergic rhinitis  
Allergic rhinitis is a global health problem affecting males and females of all ages 
from all ethnic groups and socioeconomic backgrounds (Baldacci et al. 2012). One 
of the most common allergic problems in young people is allergic rhinitis, affecting 
up to 40% of 13-14 year olds; this is closely followed by asthma which affects about 
30% of young people (International Study of Asthma and Allergies in Childhood 
1998). There are many national and international studies describing the prevalence of 
allergic rhinitis and its risk factors (Bousquet, Khaltaev et al. 2008): the International 
Study on Asthma and Allergy in Childhood (International Study of Asthma and 
Allergies in Childhood 1998) (ISAAC) specifically aimed to describe the prevalence 
and severity of asthma, rhinitis and atopic eczema/dermatitis in children living in 
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different countries and to make comparisons within and between these countries. 
Phase 3 of the study was planned to assess time trends in the prevalence of symptoms 
by repeating the cross-sectional survey from Phase 1 after at least five years. Most 
centres showed a change in the prevalence of symptoms of allergic 
rhinoconjunctivitis for the age-groups 6-7 years and 13-14 years (80% and 70% 
respectively), and in both cases the prevalence increased more often than it decreased 
for all levels of mean prevalence (Asher, Montefort et al. 2006). Data from all 
centres combined showed that the proportion of children with symptoms of more 
than one of asthma, allergic rhinoconjunctivitis and atopic eczema/dermatitis rose 
slightly from Phase 1 to Phase 3.  
1.6.1. Social and economic burden of allergic rhinitis 
Allergic rhinitis causes major illness and disability worldwide (Bousquet, Khaltaev et 
al. 2008). It is known to impact on how patients function in day-to-day life. Loss of 
sleep, inability to concentrate and risk of developing a major depressive disorder are 
common, and all impact quality of life (Blaiss et al. 2004). Work and school 
performance (Juniper et al. 1994; Walker et al. 2007) are known to be affected, 
particularly in patients with moderate/severe symptoms. Studies have shown that 
adults with allergic rhinitis experience a reduction in cognitive function and 
psychological well-being (Kremer et al. 2002), and that children with symptomatic 
allergic rhinitis had significant learning impairment in a simulated educational 
setting compared with asymptomatic controls (Vuurman et al. 1993). This 
detrimental effect has been shown to be compounded by the use of sedating H1-
antihistamines (Vuurman et al. 1996). A more recent study has shown that when 
compared with healthy controls, allergic rhinitis sufferers experience increased 
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difficulty with tasks requiring sustained attention (Hartgerink-Lutgens et al. 2009). 
Most of the economic analyses to date are based on American populations; in 2003 
the estimated annual costs of allergic rhinitis range from $2 to $5 billion (Blaiss 
2007). These estimates include indirect costs such as reduction in productivity, which 
are difficult to predict. In the UK, direct National Health Service (NHS) costs for 
managing allergic problems were estimated at over £1 billion per annum (Gupta et 
al. 2004).  
1.6.2. Measuring the impact of allergic rhinitis on quality of life  
It is widely recognised that allergic rhinitis comprises more than the classical 
symptoms such as sneezing and rhinorrhoea (Bousquet, Khaltaev et al. 2008). The 
term ‘quality of life’ (QoL) is difficult to define as it means many different things to 
different people. It can, for example, include spirituality, health and emotional status 
to name a few. Health related quality of life (HRQL) is a component of QoL that is 
determined primarily by the person’s health and that can be influenced by clinical 
interventions (Juniper 1997). It has been defined as ‘the functional effects of an 
illness and its consequent therapy upon a patient, as perceived by the patient’ 
(Schipper 1990). In the last 20 years, many health-related quality of life tools have 
been developed, some, but not all, using established principles of instrument 
development (Fitzpatrick et al. 1998). In selecting an appropriate evaluative 
instrument for the primary outcome measure of the proposed trial, only disease-
specific validated quality of life tools for rhinoconjunctivitis were considered. 
Disease-specific quality of life tool are the instruments most widely used to measure 
quality of life because they more accurately describe the problems associated with 
the disease and are more responsive to possible alterations in the quality of life when 
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compared with generic tools (Camelo-Nunes et al. 2010). A systematic review of 
patient reported outcome measures (PROMS) for asthma and allergic diseases 
(Worth et al. 2012) identified 17 PROMS specifically relating to allergic rhinitis 
(Worth et al 2012 Unpublished report). Of these only three were quality of life tools. 
The QOL-RIQ (Quality of Life Respiratory Illness Questionnaire) (Maillé et al. 
1997) was designed more specifically to measure breathing difficulties associated 
with conditions such as chronic obstructive pulmonary disease, and therefore was not 
considered appropriate for this trial.  RhinoQOL was designed to measure quality of 
life of patients with sinusitis specifically (Atlas et al. 2005) rather than 
rhinoconjunctivitis, and therefore was not considered appropriate for this trial. The 
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was one of the first tools 
to be developed by Juniper et al in 1990 (Juniper et al. 1991) and it is a widely used 
and well validated QoL measure (Juniper, Guyatt et al. 1994; Juniper et al. 2002; 
Juniper et al. 2007; Sheikh et al. 2007). The RQLQ contains 28 items in seven 
domains: activity, sleep, non-hay fever symptoms, practical problems, nasal 
symptoms, eye symptoms and emotional function. A modification was applied to the 
activity domain of the RQLQ, which allows patients to select their own activities 
rather than select from a pre-specified list of activities, allowing the activity selected 
to remain specific for that patient throughout its use in trials. The RQLQ was initially 
tested for reproducibility, responsiveness and validity in a clinical trial of patients 
with perennial rhinitis, using a nasal symptom diary for comparison (Juniper et al. 
1993). Results showed moderate correlations (r = 0.3 – 0.5) in all domains. The 
limitation of the RQLQ for use in this trial was the administration - it is 
recommended that initially an interviewer assists the patient to identify three 
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activities which are limited by their hay fever, and subsequently the RQLQ can be 
self-administered. This measure has been developed further into a standardised 
version (RQLQ(S)) (Juniper et al. 1999), where the three activity questions are 
replaced by standardised activities allowing self-administration, and this has been 
shown to have the same measurement properties and to measure the same construct 
as the RQLQ (Juniper, Thompson et al. 1999). Having identified the RQLQ as a 
disease specific quality of life tool which seemed the most appropriate for this trial, I 
visited Professor Elizabeth Juniper and discussed with her the range of tools she had 
developed. An adolescent RQLQ had been developed, but not widely validated at the 
time, and her advice was to use the standardised version of the RQLQ (RQLQ(S)) as 
it was well validated for use as a self-complete questionnaire which was necessary 
for this trial. Additionally this tool was potentially available for use electronically 
which would possibly appeal to the participants in the trial, however at the time the 
RQLQ(S) had not undergone validation in an electronic version, and Professor 
Juniper was not willing for this to be used in the trial until this exercise was 
complete, therefore paper versions were used.  
The minimum clinical important difference (MCID) is defined as “the smallest 
difference in score in the domain of interest which patients perceive as beneficial and 
which would mandate, in the absence of troublesome side-effects and excessive cost, 
a change in the patient’s management” (Juniper et al. 1994). The MCID for the 
RQLQ has been estimated as 0.5 (Juniper et al. 1996); and a validation study of the 
RQLQ(S), which compared responsiveness and the MCID of the RQLQ and 
RQLQ(S) in 83 patients, showed very good responsiveness for both instruments and 




Allergic rhinitis is linked to other inflammatory diseases affecting respiratory 
mucous membranes (Greiner, Hellings et al. 2011). In particular, allergic rhinitis and 
asthma frequently coexist, with population surveys estimating that up to 40% of all 
allergic rhinitis patients have asthma and that 80% of patients with asthma also have 
allergic rhinitis (Leynaert et al. 2000; Casale et al. 2004; Walker et al. 2005). Other 
co-morbidities include allergic conjunctivitis, allergic sinusitis and atopic 
eczema/dermatitis. Allergic rhinitis and asthma are highly prevalent conditions and 
cause substantial health and economic burden to the individual (Vandenplas et al. 
2010), and the impairment of quality of life experienced by patients with rhinitis is at 
least as severe as that of patients with asthma (World Health Organization Initiative, 
Bousquet J et al. 2001). 
1.7. Aetiology and risk factors 
As discussed above, the symptoms of hay fever are caused by an IgE-mediated type 
1 hypersensitivity reaction to grass, tree, or weed pollens. Allergy to other seasonal 
aeroallergens such as fungal spores may also provoke symptoms. Seasonal allergic 
conjunctivitis results in eye itching and watering and is often associated with allergic 
rhinitis, commonly in children and young adults sensitised to tree or grass pollen. 
Typically, symptoms become worse during the relevant pollen season, and outdoors 
when pollen exposure is increased. Risk factors include a personal or family history 
of atopy or other allergic disorders, high socioeconomic status (Jones 2004), birth 
order (Strachan 1989) (increased risk being seen in first born), and small family size 
(Greiner, Hellings et al. 2011). 
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1.7.1. Measuring pollen counts 
Sites throughout the UK report daily pollen counts for the most allergenic pollens 
such as grass, birch, oak and nettle, however, over 90% of hay fever sufferers are 
affected mainly by grass pollen in temperate regions (Emberlin 1997). The grass 
pollen season can vary from year to year because of its onset, total seasonal 
cumulative count and severity in terms of the number of days with high counts, and 
this can be attributed to weather variations and environmental factors (Emberlin et al. 
1999). This is important in considering the timing of prophylactic pharmacotherapy. 
At the time of this trial, pollen data were collected and collated by the National 
Pollen and Aerobiology Research Unit (NPARU) at the University of Worcester 
(http://www.worcester.ac.uk/discover/national-pollen-and-aerobiology-research-
unit.html). The pollen count is a measure of the number of pollen grains of a certain 
type per cubic metre of air sampled, averaged over 24 hours. Pollen monitoring sites 
around the UK have a Burkard volumetric spore trap. These are usually located on 
the roof of a suitably accessible building to enable the ambient airflow to be 
monitored. This generally catches a good mix of local and distant pollen sources 
carried by the wind.  
1.8. Diagnosis and investigations 
A number of diagnostic tests are available to confirm a diagnosis of allergic rhinitis. 
A clinical assessment and evidence of an aero-allergen trigger is generally sufficient 
to make a diagnosis in the case of hay fever (Walker et al. 2006), however a study 
comparing a structured allergy history and skin prick testing (SPT) with patient’s 
self-report, or a structured allergy history alone, showed that combining a structured 
allergy history and SPT improved the accuracy of an assessment of allergic status 
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(Smith et al. 2009). Specific IgE reactivity to relevant aeroallergens can be measured 
either by SPT or measuring IgE in serum samples. Skin prick testing involves 
introducing a very small drop of purified allergen extract into the skin, which is 
punctured by a 1mm lancet. The aeroallergens chosen for an allergic rhinitis 
diagnosis are usually mixed grass and tree pollen, any other aeroallergens suggested 
by the presenting history, plus a positive and negative control. After 10-15 minutes, 
any resulting wheal and flare response is recorded as the mean of a vertical and 
horizontal diameter, and generally a reaction with a mean diameter 3mm bigger than 
the negative control is considered to be positive (EAACI Subcommittee 1993). 
Although skin prick testing of aeroallergens is considered to be safe, very little 
testing is carried out in primary care (Smith, Hogger et al. 2009). High serum IgE 
concentrations can be indicative of IgE-mediated disease, however there is overlap 
between atopic and non-atopic ranges (Burney et al. 1997) and this test is of limited 
use. Laboratory allergen specific IgE tests such as ImmunoCAP (Phadia, Uppsala, 
Sweden) are available but not routinely used for allergic rhinitis diagnosis 
confirmation (Walker, Morton et al. 2006).  
1.9. Management and treatment 
The aim of treatment for people with allergic rhinitis is to achieve safe and effective 
relief from symptoms; a multi-faceted approach may therefore contain patient 
education, minimisation of allergen contact, pharmacotherapy and consideration of 
immunotherapy (Greiner, Hellings et al. 2011). Recommendations in the British 
Society for Allergy and Clinical Immunology Guidelines for the treatment of allergic 
rhinitis (Scadding, Durham et al. 2008) are presented with a grade of 
recommendation based on the reviewed literature. For example, topical nasal 
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corticosteroids are considered to be the treatment of choice for moderate to severe 
disease (Grade of recommendation A). Consideration of alternative approaches to 
pharmacotherapy such as allergen avoidance suggests little evidence for their 
effectiveness (Greiner, Hellings et al. 2011). Concordance with any prolonged 
treatment regime is crucial, and education about the disease and mode of application 
and safety of treatment are vital to achieve this (Scadding 2008). 
The principle treatment options for managing allergic conditions are: 
 Allergen avoidance 
 Pharmacotherapy 
 Immunotherapy 
These are briefly considered below. 
1.9.1. Allergen avoidance 
Allergen avoidance is recommended, where possible and appropriate, as first-line 
treatment for managing allergic conditions, and it is therefore important to identify 
the allergen and give advice on practical strategies for allergen avoidance. In patients 
suffering from intermittent symptoms, exposure to grass or tree pollens are the most 
common trigger. Tree pollens are particularly prevalent in the spring (February to 
May) and grass pollens in the early summer (May to July). Although complete 
allergen avoidance is practically impossible to achieve, obvious measures such as 
closing windows in the early evening, avoiding grass cutting and outdoor activity 
when pollen counts are high are simple and may help some people, although there is 
little scientific evidence to support this. Accurate identification of the pollen/allergen 
using objective allergy tests such as skin prick tests, detection of serum specific IgE 
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and nasal provocation challenge testing may help to advise patients when to take 
prophylactic allergic rhinitis treatment (Sheikh et al. 2005; Shehata et al. 2007). 
1.9.2. Pharmacotherapy 
A systematic review of the RCT literature on the effectiveness of common 
pharmacological treatment used in hay fever in people aged 12 (Sheikh et al. 2009) 
and over is summarised in Table 1.3. These treatments aim to minimise or eliminate 
symptoms, optimise QOL, and reduce the risk of developing co-morbidity. 
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Table 1.3: Treatment for hay fever (from Clinical Evidence 2009;10:509) 
  
Treatments of hay fever 
Beneficial  
 Intranasal antihistamines (e.g.azalestine) 
 Intranasal corticosteroids  
 Oral antihistamines (acrivastine, azatadine, brompheniramine, cetirizine, 
levocetirizine, ebestine, fexofenadine, loratidine, destoratidine, rupatadine, and 
mizolastine) 
 Oral antihistamine plus pseudoephedrine plus (reduces nasal symptom severity 
compared with antihistamines alone) 
Likely to be beneficial 
 Intranasal antihistamines (levocabastine and olopatadine) 
 Leukotriene receptor antagonists (oral) 
 Systemic corticosteroids 
Unknown effectiveness  
 Intranasal ipratropium bromide 
 Oral decongestants 
Unlikely to be beneficial 
 Oral antihistamines plus leukotriene receptor antagonists (seem no more effective 
than either treatment alone) 
Likely to be ineffective or harmful 







Allergen-specific immunotherapy involves administering gradually increasing 
quantities of an allergen extract to which an individual is sensitised, over a prolonged 
period of time. Treatment aims to induce clinical and immunological tolerance, has 
long-term efficacy and may prevent the progression of the disease (Bousquet, 
Khaltaev et al. 2008). Immunotherapy is most commonly administered as 
subcutaneous injections, but may also be delivered by the sublingual route (Walker et 
al. 2011). At present, immunotherapy is confined to use in specialist centres because 
of the risk of serious allergic reactions (Calderon et al. 2007), and is recommended in 
patients whose symptoms did not respond to adequate pharmacotherapy. Sublingual 
immunotherapy has been shown to be a safe treatment (Wilson et al. 2005; Walker, 
Durham et al. 2011), where only the first dose needs to be given under supervision. 
1.10. Shortcomings of provision of allergy services in primary care 
A report published in 2003 Allergy – the unmet need, commissioned by the Royal 
College of Physicians, clearly demonstrated current deficiencies in NHS allergy 
services in the UK, and made a number of proposals to improve patient care, both in 
primary and secondary care. In 2004, the House of Commons Select Committee on 
Health (Health Committee 2004) reported that ‘serious problems exist in the current 
provision of allergy services in the UK’, and ‘those working in primary care lack the 
training, expertise and incentives to deliver services’. These findings have been 
confirmed in relation to allergic rhinitis in a survey of general practitioners whose 
practice had a self-declared interest in the management of allergic and respiratory 
disorders (Ryan et al. 2005). There was considerable variation in the awareness and 
management of allergic rhinitis. In 2010, a follow-up report - Allergy services – still 
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not meeting the unmet need (Royal College of Physicians 2010) reported the 
continuing deficiencies in allergy service provision, and stated that there had been 
little progress in the governance and training of primary care providers who were 
managing allergic diseases.  
The House of Lords Science and Technology Committee report on Allergy (House of 
Lords Science and Technology Committee 2006-7) recommended that the 
Department for Children, Families and Schools should review the clinical care that 
children receive at school, and should reassess the way they are supported through 
the examination season. However, the knowledge and training in allergic diseases of 
teachers and support staff may not be sufficient to support children though this 
period (House of Lords Science and Technology Committee 2006-7). Enhancing the 
role of primary care professionals in ensuring control of allergy symptoms by 
improving training and engaging the patient may be a more beneficial and safer 
approach.  
 
1.11. Literature review of educational interventions in primary care 
There are a broad range of interventions which aim to improve health care 
professional practice in primary care and these have been widely reported in a 
number of systematic reviews (Oxman et al. 1995; Freudenstein et al. 1999; 
Grimshaw et al. 2001; Wensing 2008). The interventions reviewed include different 
approaches to changing professional behaviour, which broadly fit the following 
strategies (Grimshaw, Shirran et al. 2001): 
 Educational materials – distribution of published or printed recommendations 
for clinical care including clinical practice guidelines. 
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 Conferences – participation of health care providers in conferences, lectures, 
workshops or traineeships. 
 Local consensus process – inclusion of participating providers in discussion 
of the clinical problem and solution to ensure it is appropriate locally. 
 Educational outreach visits – use of a trained person who meets the providers 
in the health care setting to provide information with the aim of changing the 
provider’s performance. 
 Patient-mediated interventions: any intervention where specific information is 
sought from or given to patients, e.g. direct mailing to patients, educational 
materials given to patients. 
 Audit and feedback – any summary of clinical performance given over time, 
e.g. average number of prescriptions given or tests ordered, which may also 
include a recommendation for clinical care. 
 Reminders (manual or computerised) – a prompt that reminds the health care 
provider to perform a patient or encounter specific clinical action, e.g. 
measuring blood pressure annually. 
 Marketing – use of personal interviewing, discussions groups or a survey of 
targeted providers to identify barriers to change. 
 Multi-faceted interventions – any intervention that includes one or more of 
the above. 
 
Grimshaw et al (2001) concluded that the more passive dissemination strategies such 
as mailing educational materials to targeted clinicians is generally ineffective when 
used alone to change behaviour, but may be helpful for raising awareness of the need 
37 
 
for change (Grimshaw, Shirran et al. 2001). Audit and feedback and the use of local 
opinion leaders had variable effectiveness, whilst strategies such as educational 
outreach and reminders were reported to be generally effective. The evidence 
specifically from primary care interventions is variable. A review of the evidence of 
the effectiveness of educational interventions for GPs for health outcomes for 
patients with asthma (Barton et al. 2003) identified three RCTs where the educational 
intervention included health professional education and the effects of the intervention 
on patient health outcomes were reported (White et al. 1989; Smeele et al. 1999; 
Clark et al. 2000).  Clark et al (2000) evaluated an interactive seminar for GPs, and 
showed a short-term improvement in a subset of intervention group patients; these 
patients who had received an inhaled corticosteroid during the trial had fewer 
hospital admissions and scheduled visits for asthma but, after two years, only the 
reduction in hospital visits was sustained (Clark, Gong et al. 2000).  
 
The second study identified in the review was an investigation into the effectiveness 
of an intensive small group education and peer review programme, The intervention 
aimed to educate GPs on the aims of the national guidelines on asthma/chronic 
obstructive pulmonary disease (COPD), including diagnosis, treatment, review and 
patient education (Smeele, Grol et al. 1999). The intervention consisted of four, two-
hour intensive, interactive group education and peer review sessions. Patient 
outcomes included disease specific quality of life, current smoking and symptoms, 





The educational intervention in the third study involved seven small group seminars 
and group discussion focussing on asthma management strategies (White, Pharoah et 
al. 1989). Self-completed morbidity questionnaires were used to assess patient 
outcomes at six-monthly intervals over two years.  There was no difference in 
morbidity between the groups before or after the intervention.  
 
This review concluded that the three studies provided minimal evidence for the 
effectiveness of the different brief continuing medical education models used for 
improving health outcomes of patients with asthma treated in primary care (Barton, 
Sulaiman et al. 2003).  
 
A cluster randomised controlled trial of educational interventions to improve 
detection rates for dementia in primary care compared three different approaches to 
the mode of delivery (Downs et al. 2006). An electronic tutorial on CD Rom which 
enabled learning from case analysis, a decision support software incorporated into 
the existing medical record software used in primary care, which gave prompts for 
the investigation and management of dementia, and small group workshops with GPs 
and practice nurses led by experienced GPs with a background in postgraduate 
education, were compared with a control group. Outcomes for this study were 
detection rates and concordance with guidelines; there were no patient-level 
outcomes. There were significant improvements in rates of reported cases of 
dementia with decision support software and practice-based workshops compared 
with the control group, however there was no difference in concordance with 
guidelines. This improvement may however have resulted from baseline differences, 
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Decision support software is considered to be a simple and practical intervention to 
implement in primary care. This study was included in a systematic review of the 
effects of educational interventions on primary care dementia (Perry et al. 2011), 
which showed moderately positive effects of educational interventions on dementia 
detection and diagnosis in primary care. Similar studies of educational interventions 
for suicide prevention (Morriss et al. 2005) and management of breast/ovarian cancer 
cases (Watson et al. 2001) conclude that brief interventions show only moderate 
effects which in some cases are not sustained. 
 
More multifaceted interventions based on assessment of potential barriers to change 
have been reported to be the most effective (Grimshaw, Shirran et al. 2001). A 
cluster trial of a package of training for health visitors to identify symptoms of 
depression post-natally and to provide one-to-one sessions with participants was 
clinically effective in reducing depressive symptoms (Morrell et al. 2009), however 
Puder et al (2011) undertook a multifaceted lifestyle intervention to improve aerobic 
fitness and reduce body mass index (BMI) in preschool children (Puder et al. 2011), 
and used workshops, lessons, home activities, extracurricular activities and 
medications in the environment. Despite this intense level of intervention there was 
no change in BMI in preschool children, one of the primary outcome measures. 
Combinations of complex organisational and educational interventions for physicians 
and patients, together with enhanced involvement of health care professionals have 
been shown to improve depression outcomes in primary care (Gilbody et al. 2003). 
Similar complex multifaceted primary care trials reported no difference in primary 




Educational interventions for health professionals are important for improving the 
quality of health care (Wensing 2008), however there is a large variation in their 
effectiveness and it is difficult to predict from the evidence in the literature whether 
any intervention will lead to improved patient outcomes. When planning the trial 
presented in this thesis, this variable evidence was outweighed by the fact that short 
courses are routinely used as an educational tool by the NHS, and if this cheap 
educational intervention may have the potential to (Clark, Gong et al. 2000; Downs, 
Turner et al. 2006) impact patient outcomes, evidenced by a well-powered cluster 
randomised trial, there was benefit in testing it.  
 
1.12. Systematic review of educational interventions in primary care 
targeting adolescent hay fever. 
 1.12.1. Introduction 
Any intervention should be evidence based and rigorously evaluated prior to 
implementation in routine care. The need for an intervention to improve outcomes 
for adolescents with hay fever is clear, the prevalence is high in this population 
(International Study of Asthma and Allergies in Childhood 1998), and loss of 
productivity, poor academic achievement and loss of quality of life are well 
documented (Vuurman, van Veggel et al. 1993; Juniper, Guyatt et al. 1994; Kremer, 
den Hartog et al. 2002; Blaiss and Group 2004; Walker et al. 2007). Sheikh et al 
2007 (Sheikh et al. 2007) showed that an educational intervention in primary care 
targeted at adults with perennial rhinitis had a moderate effect on patient outcomes. 
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This systematic review aimed to find any similar trial targeting adolescents with hay 
fever. 
 
 1.12.2. Methods 
Criteria for considering studies for this review 
Types of studies 
This review was limited to randomised controlled trials. 
 Types of participants 
All patients aged 12-18 years (adolescents) with a current seasonal allergic rhinitis 
diagnosis were included. 
Types of interventions 
Any educational intervention was included. 
Types of outcomes 
Outcomes were limited to quality of life for seasonal allergic rhinitis 
Search methods for identification of studies 
Literature was searched from 1946 to April 2014. Medline, Embase and the 
Cochrane Central Register of Controlled Trials were searched; there were no 
language restrictions applied. 
 
The search strategy for Medline and Embase was: 
1. Rhinitis, Allergic, Seasonal/ 
2. Adolescent/ 
3. educational intervention.mp. 
4. Primary Health Care/ 




The search strategy for Cochrane Library was: 
seasonal allergic rhinitis and educational interventions. 
 
 1.12.3. Results 
There were no eligible studies. The searches revealed two conference abstracts 
relating to the current trial (Hammersley et al. 2010; Hammersley et al. 2010), the 
current trial protocol (Hammersley et al. 2010) and one further study (Mendez et al. 
2008) (see Figure 1.1). After screening of the one study not related the current trial 
this was excluded as although it was an educational intervention targeted at primary 






Figure 1.1 Study Flowchart (PRISMA template) 
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 1.12.4. Discussion 
The search criteria for this systematic review were very specific; evaluations of 
educational interventions targeting primary health care professionals, reporting 
outcomes at the patient level and therefore it is not surprising that there were no 
relevant studies found. This finding therefore provided a clear rationale for the 
planned evaluation of an educational intervention in a primary care setting. 
 
1.13. Context of the project development and rationale for the trial 
The trial described in the thesis developed as a result of a successful Chief Scientist’s 
Office (CSO) Research Training Fellowship application. In planning my CSO 
application I discussed research ideas with the senior academic staff in the Centre for 
Population Health Sciences. Professor Sheikh and Dr Walker (from Education for 
Health) had recently published a randomised controlled trial of an educational 
intervention for perennial rhinitis in adults (Sheikh, Khan-Wasti et al. 2007) and 
were interested in extending this work to explore a similar educational intervention 
for seasonal allergic rhinitis in adolescents. The requirements for the CSO 
Fellowship were to independently undertake a research project and complete a 
programme of research training. In collaboration with Professor Sheikh and Dr 
Walker I developed a proposal for a randomised controlled trial, and to register for a 
PhD as my research training. During the interview for my CSO Fellowship, we 
discussed the merits of a cluster randomised controlled trial methodology for 
evaluating educational interventions, and it was agreed that this trial would add 
valuable evidence if this approach was used, rather than a parallel group design; 
however it was also acknowledged that recruitment into cluster trials can be more 
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difficult and this part of the trial may be challenging. I was awarded a part-time 
research training fellowship for three years and registered for a part-time PhD.  
 
The clinical basis for a trial of an educational intervention for hay fever in all age 
groups is clear, as despite the availability of cost-effective medicines and the grade A 
evidence of their efficacy (Sheikh, Panesar et al. 2009), morbidity from allergic 
rhinitis remains high (International Study of Asthma and Allergies in Childhood 
1998) resulting in unnecessary symptoms, leading to time off school/work and 
therefore loss of productivity and a reduction in QoL for allergic rhinitis sufferers 
(Juniper, Guyatt et al. 1994).   
 
Evidence that hay fever is a particular problem for adolescents comes was presented 
in a  case-control study (Walker, Khan-Wasti et al. 2007) which investigated whether 
seasonal allergic rhinitis adversely impacts examination performance in UK 
teenagers. This was the first study looking at the effect of hay fever on examination 
performance, which is pertinent due to the General Certificate of Secondary 
Education (GCSE) examinations and peak grass pollen counts occurring 
simultaneously from mid-May to the end of June. Walker et al(Walker, Khan-Wasti 
et al. 2007)  focussed on examinations in three core subjects taken by all students, 
namely Mathematics, English and Science (Walker, Khan-Wasti et al. 2007). Young 
people with seasonal allergic rhinitis symptoms were 40% more likely to drop a 
grade between their practice and final GCSE examinations (odds ratio: 1.43; 95% CI 
1.13-1.18), and 70% more likely to drop a grade if they reported taking sedating 
antihistamines at the time of their examinations (odds ratio: 1.71; 95% CI 1.06-2.75).  
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The achievement of optimal outcomes in young people with hay fever depends on 
timely diagnosis, followed by implementation of measures to reduce allergen 
exposure, selection of safe and effective treatments and patient adherence to 
therapeutic regimens. This could possibly be facilitated by appropriately trained 
health care professionals who in turn can educate patients in the optimum treatment 
choices, which aim to: minimise or eliminate symptoms, optimise QoL and reduce 
the risk of developing co-morbidities, optimise timing of medication commencement, 
and improve techniques to ensure appropriate delivery of intranasal treatments. 
 
A multi-centre community based RCT trial showed that standardised allergy 
education given to health care professionals improves disease-specific quality of life 
in adult patients with perennial rhinitis (Sheikh, Khan-Wasti et al. 2007). This 
collaborative study was carried out by The University of Edinburgh and Education 
for Health and found that a structured educational intervention was feasible to deliver 
in primary care and improved outcomes in adults with perennial rhinitis. This 
educational intervention was a six month diploma, distance learning allergy course 
supported by study days and examinations. This approach to continuing professional 
development requires considerable investment in time and resources, and given that 
much of healthcare professional’s training is delivered in short course format, 
Education for Health developed an intensive short course focussing specifically on 
allergic rhinitis and asthma which was derived from one module of the diploma 
course. This short course was well attended and received by health care 
professionals, indicated by internal course evaluation (data not available), but had not 
been evaluated formally in terms of improved patient outcomes. Building on these 
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earlier studies (Sheikh, Khan-Wasti et al. 2007; Walker, Khan-Wasti et al. 2007) and 
the suggestion that short courses were more convenient and acceptable to busy 
primary healthcare professionals, this trial sought to evaluate whether Education for 
Health’s intensive short course could improve outcomes for adolescents with hay 
fever.   
1.14. Aims of the trial 
The aims of this trial were therefore to: 
 Establish the effectiveness of standardised allergy training for primary 
health care professionals in increasing disease-specific QoL of adolescents 
with hay fever 
 Assess whether primary care-based health care professionals attending a 
hay fever focused intensive short course can enhance their self-assessed 
competence and confidence in managing adolescents with hay fever 
 Measure any differences in clinical practice, consultations and/or 
prescribing between the control and intervention arms 
 Assess any reduction in adolescent hay fever symptoms 
 
Summary 
This chapter presented the background information considered in the development of 
the trial. Consideration was given to the prevalence of hay fever and other allergic 
disorders, what current primary care treatment options are recommended in line with 
evidence-based guidelines current at the time of the intervention used in the trial, 
how hay fever affects the QoL of sufferers and how interventions may help this. The 
findings of the literature review of educational interventions in primary care were 
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unclear as to their benefits in terms of patient outcomes, however the results of the 
systematic review provided a clear rationale for proceeding with the cluster trial. The 
next chapter discusses the rationale for deciding to undertake a cluster RCT design 





Chapter 2 – Methodology 
Having outlined the background to the trial, this chapter will involve a review of 
existing guidance for carrying out a cluster RCT of an intensive short course in 
primary care, and in particular the specific methodological considerations of cluster 
randomised trials, which informed the decisions made in the trial design. 
2.1. Introduction 
When planning and designing a research study it is important to consider all possible 
approaches and methods that best address the research aims proposed. The 
theoretical framework which underpins a quantitative approach aligns itself with a 
positivist paradigm: that a single reality exists that can be measured (Kuper et al. 
2008). Quantitative research is a formal objective deductive approach in which cause 
and effect can be explored, whilst the researcher strives to remain independent to the 
evaluation being undertaken (Malterud 2001). This is in direct contrast to a 
qualitative or naturalistic approach, where the researcher becomes an active 
participant in the research with the aim of developing a rich understanding of what 
people are actually experiencing and indeed identifying new research questions from 
this (Malterud 2001). Rather than believing that one reality exists, qualitative theory 
holds that the reality perceived is constructed by social, historical and individual 
contexts (Kuper, Reeves et al. 2008). Qualitative research is thus a more informal, 
subjective inductive approach used to develop theory rather than test it, and is used to 
explore, for example, social experience, attitudes and meanings, processes relating to 
interactions, all of which are integral components of clinical knowledge. 
Acknowledging the strengths and limitations of both quantitative and qualitative 
paradigms has led some to consider, where appropriate, a mixed-methods approach, 
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where qualitative and quantitative methods are integrated within the same study 
(Cresswell et al. 2012). This assumes that the knowledge gained from each analysis 
is complementary and enriching.  
2.2. Complex interventions   
Complex interventions are described as interventions that contain several interactive 
components (Medical Research Council 2000). One could argue that no intervention 
is simple, but the number of possible dimensions of complexity varies. The original 
Medical Research Council (MRC) guidance on developing and evaluating complex 
interventions (Medical Research Council 2000) proposed a framework (Figure 2.1) 
to help researchers develop appropriate methods and this has subsequently been 
revised and updated (Craig et al. 2008). The framework advocates a flexible phased 
approach similar to that used in developing and testing drugs, which are: 
 Development: exploring relevant theory to ensure the best choice of 
intervention and hypothesis, which includes developing a theoretical 
understanding of the likely process of change and may involve generating 
new evidence, and modelling to identify the components of the intervention 
and the underlying mechanisms by which they will influence outcomes;  
 Feasibility and piloting: testing components of a replicable intervention, 
assessing acceptability, compliance, delivery of the intervention, recruitment 
and retention and estimates of effect size, and as discussed in Section 2.1 a 
mixed methods approach is likely to be needed to understand many of these 
important factors;  
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 Evaluation: consideration of all study designs available which suit different 
questions, choosing appropriate outcome measures, measuring processes 
which will be key to understanding causal mechanisms and outcomes. 
 Implementation: getting evidence into practice is a fundamental premise of 
all research and the evidence should be available in accessible formats and 
disseminated widely. 
 
Figure 2.1: Key elements of the development and evaluation process (taken 
from Developing and evaluating complex interventions: the new Medical 




Feasibility and piloting 
Testing procedures 
Estimating recruitment and retention 




Understanding change process 
Assessing cost effectiveness 
Implementation 
Dissemination 
Surveillance and monitoring 
Long-term follow-up 
Development 
Identifying the evidence base 
Identifying  or developing the theory 
Modelling process and outcomes 
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2.3. Randomised controlled trials 
RCTs represent the methodology of choice for assessing the effectiveness of a health 
care intervention because of the unique ability to control for known and unknown 
confounding factors (Sheikh et al. 2002). For studies where the natural unit of 
analysis is the patient, but the intervention is delivered to a unit such as a general 
practice, it is necessary to conduct a cluster RCT in order to minimise the risk of 
contamination (Campbell et al. 2012). Cluster randomised designs are often used for 
intervention studies in primary care, where naturally occurring units or clusters such 
as general practices exist (Raab et al. 2001). Examples of this in primary care include 
a trial of obesity management (Moore, Summerbell et al. 2003), practice nurse 
training in the use of asthma action plans (Cleland et al. 2007), pharmacist led statin 
outreach support (Lowrie et al. 2010) and a pharmacist intervention to reduce 
medication errors in primary care (Avery et al. 2012).  
2.4. Justification for a cluster RCT  
There are a number of reasons to randomise at the cluster rather than at the individual 
level: 
 The intervention occurs at a cluster level such as health care interventions in 
practices, hospitals or communities. 
 To eliminate contamination of the intervention effects between patients in the 
cluster 
 Patients in one cluster are likely to have similar outcomes. 
 
Ukoumunne et al (1999) identified the following methodological problems with 
cluster trials (Ukoumunne et al. 1999): 
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 The level of the intervention may differ from the level of the evaluation 
 There may be a small number of clusters 
 Outcomes of individuals are often correlated within clusters. 
Once randomising by cluster has been decided, these problems must be accounted for 
in the design, analysis and reporting of the trial, as lack of independence between 
patients in a cluster RCT has important statistical implications for sample size 
calculations and analysis (Eldridge et al. 2012). The CONSORT (Consolidated 
Standards of Reporting Trials) statement (Moher et al. 2001; Schulz et al. 2010) on 
trial conduct and reporting has been extended to take into account the special features 
of cluster RCTs (Campbell et al. 2004; Campbell, Piaggio et al. 2012), such as the 
rationale for cluster design, and implications of the cluster effect in design and 
analysis. A cluster RCT was the most appropriate design for this trial of a complex 
educational intervention delivered to health care professionals in primary care to 
avoid contamination between groups, and to account for the two levels, (the general 
practice and the patient). The implications on design, conduct, analysis and 
interpretation (Campbell, Piaggio et al. 2012) are considered below. 
2.5. Design 
2.5.1. Random allocation and minimisation 
An essential part of RCTs is the process of allocating units (in this study the unit of 
allocation was the general practice) to the intervention and control arms. This process 
is known as randomisation and is essential to minimise systematic bias during the 
selection stage of a trial (selection bias). Randomisation ensures that any differences 
that are found between the two groups following an intervention can only be due to 




Minimisation is a method of trial allocation useful in trials with a small number of 
clusters and aims to ensure that treatment arms are balanced in terms of predefined 
patient factors as well as patient numbers in each group (Scott et al. 2002). It was 
originally described by Taves (Taves 1974) and Pocock (Pocock et al. 1975) in the 
mid-1970s, but despite being recommended for use in clinical trials it is not widely 
adopted as a method for allocation to trial arms in clinical trials. It is a non-random 
method of treatment allocation and can be criticised, as assignment to treatment arms 
may be predicted (Scott, McPherson et al. 2002). 
2.5.2. Sample size considerations 
When planning a cluster RCT, the standard methods for calculating a sample size 
that allow a reasonable chance of detecting a pre-determined difference in outcomes 
are not sufficient. The design of a cluster RCT is not as efficient as a trial that has 
used individual randomisation where outcomes are independent if the evaluation is at 
the individual level. This lack of independence may increase the size of the standard 
errors, widen confidence intervals and increase p values compared with a study of 
the same size using randomisation at the individual level (Campbell et al. 2000). The 
loss of statistical power resulting from a cluster design can be compensated by a 
statistical measure known as the ‘intracluster correlation coefficient’ (ICC) and to 
achieve the same power as an individual level randomisation, standard sample sizes 
need to be inflated by a factor known as the ‘design effect’  or ‘variance inflation 
factor’ (Donner et al. 2000 ). The design effect is defined as the ratio of the total 
number of participants required using cluster randomisation to the number required 
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using simple randomisation to detect the same treatment effect (Kerry et al. 2001). 
This is calculated using the equation: 
1 + (n - 1) ρ 
where n is the average cluster size and ρ is an estimate of the ICC (Campbell, 
Mollison et al. 2000). Estimates of the design effect are ideally based on previously 
reported trials, which are as similar as possible in terms of size of cluster, types of 
individuals the intervention is aimed at and outcome measures used. There is little 
published literature about the likely design effect in health care interventions and hay 
fever quality of life, and despite the CONSORT guidance (Campbell, Piaggio et al. 
2012), few studies in primary care report the estimated effect size and its precision, 
and an ICC for each primary outcome.  
2.6. Analysis  
The unit of analysis in a cluster RCT can be either the cluster level or the individual 
participants provided the clustering effect is accounted for. It is widely accepted that 
individuals within the same cluster (e.g. general practice) may be more similar than 
individuals selected at random (Campbell, Mollison et al. 2000). This lack of 
independence or correlation leads to loss of statistical power compared with 
individual patient randomisation, which needs to be accounted for in the analysis. 
For this reason, the use of standard statistical techniques commonly used in RCTs of 
individuals are not appropriate for cluster RCTs (Mollison et al. 2000; Lancaster et 
al. 2010). Failure to adjust for the clustering effect will give misleading results. 
Multi-level analyses that take account of both individual and cluster-level effects are 




2.6.1. Missing data 
Poor compliance in clinical trials collecting quality of life data is well recognised 
(Fielding et al. 2008) as with most areas of research. Missing data are more likely to 
occur with quality of life data than with clinical data for example, because they are 
generally self-administered and follow-up questionnaires are often posted to 
participants numerous times throughout a study, rather than being collected face-to 
face (Fielding et al. 2012). The most fundamental information to ascertain when 
attempting to deal with missing data is the reason for ‘missingness’, as this has 
implications for the risk of bias that is associated with the missing data. Data may be 
missing for a variety of reasons, which are widely reported in the literature (Sterne et 
al 2009). Three main mechanisms defined by Rubin (Rubin 1976) are: 
 Missing completely at random (MCAR): i.e. there are no systematic 
differences between the missing and observed values. 
 Missing at random (MAR): Any systematic difference between the missing 
values and the observed values can be explained by differences in observed 
data. 
 Missing not at random (MNAR): Even after the observed data are taken into 
account, systematic differences remain between the missing and the observed 
values. 
Approaches to dealing with missing data include simple imputation, where a single 
estimate value for the missing observation is obtained (Fielding, Fayers et al. 2008), 
or multiple imputation where several different plausible imputed datasets are created 
and combined to obtain results from each of them. Complete case analysis is 
criticised in the literature for not taking account of the potential bias, however if data 
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are missing completely at random, there may be justification for a complete case 




Chapter 3 – Methods 
The study design used was a cluster RCT. The unit of randomisation was the 
general practice. The health care professional at each trial site provided enhanced 
care (intervention) or current care (control) to adolescents suffering from hay fever. 
The trial took place over two summers: 2009 and 2010, in general practices in 
Scotland and England.  
 
A protocol of the methods used in this cluster RCT was published in advance of 
analysis (Hammersley, Elton et al. 2010). The trial was registered on the Current 
Controlled Trials register: ISRCTN95538067. 
3.1. Research ethics and research & development approval 
The study was initially approved by Lothian Research Ethics Committee 02 
(Reference 08/S1102/37) (see Appendix 1 for approval letter). In year 1 of 
recruitment, a substantial amendment was accepted by the ethics committee to 
extend the recruitment period for an additional year and broaden the recruitment base 
as described in Section 3.3.1 below (see Appendix 1 for approval letter). R&D 
approval was obtained from NHS Lothian, NHS South of Tyne and Wear, NHS 
North of Tyne, NHS County Durham, NHS North Yorkshire and York and NHS 
Leeds (see Appendix 1 for approval letters). The clinical trial was conducted 
according to the Helsinki Declaration (World Medical Association Declaration of 
Helsinki) and Good Clinical Practice Guidelines (Medical Research Council 1998).  
3.2. Setting 
The trial took place across Edinburgh, Lothian and Borders, Durham and Tees 




3.3.1. Recruitment of general practices 
In the first year of the trial, the Scottish Primary Care Research Network (SPCRN) 
was approached for their assistance with practice recruitment in Lothian and Borders. 
They were asked to recruit 25 practices. SPCRN wrote to their member general 
practices informing them of the study with an information flyer. Where practices 
expressed an interest in participating, an information sheet and consent form was sent 
to each practice with the offer of a face-to-face or telephone discussion at which the 
study was explained in more details. A member of the practice team (Lead GP or 
Practice Manager) then signed a consent form if the practice decided to participate. 
Practices were asked to nominate a health care professional who regularly saw 
patients with hay fever, but who had not received postgraduate allergy training in the 
previous 12 months, to take part in the trial. After three months of recruitment effort 
by SPCRN only eight practices had been recruited. Following discussion with GP 
colleagues in the Centre for Population Health Sciences and the Trial Management 
Group, a variety of alternative methods were used to increase the uptake of the trial 
in Lothian and Borders: 
 Increased SPCRN mailing in Lothian and Borders followed by 2-3 telephone 
calls to practice managers/lead GPs 
 Contact was made with general practices in Scotland via NHS Education for 
Scotland 
 The Scottish Practice Nurse Association were contacted and agreed to mail 
information to their members and put a flyer on their website 
 Education for Health mailed Scottish practice nurses on their training register 
60 
 
 Local Health Partnership practice nurse leads in Lothian agreed to advertise 
the trial at their meetings 
 Local informal contacts were asked to discuss the trial with their practices 
I delivered poster and oral presentations at seminars organised by the Centre 
for Population Health Sciences. 
Despite this effort to increase the awareness of the trial in Lothian and Borders, we 
were unable to recruit any further practices. Following a discussion with a senior 
academic in CPHS who was working with English practices, I contacted the 
Northern and Yorkshire Research Network (NYREN), who have a different model 
for general practices to engage in research, which includes financial reimbursement. 
They have a membership of ‘research ready’ practices who are committed to take 
part in research annually, as well as practices who are aiming to become research 
ready. Following a successful application process to NYREN and all the additional 
ethics and R&D approvals being in place, 11 practices were recruited in just over 
three weeks via NYREN. Figure 3.1 shows recruitment of general practices over the 
two years, demonstrating the slow recruitment rate in the first year compared with 




Figure 3.1: Cumulative practice recruitment over two years from two primary 
care research networks. 
 
3.3.2. Recruitment of adolescents 
Patients with a recorded diagnosis of hay fever (Read code clinical terms v2: H17), 
and/or evidence of use of hay fever medication in the previous two years (oral 
antihistamines and topical steroids, drugs used in nasal allergy and topical nasal 
decongestants; Read code clinical terms v2: c8, c6, 18 and 19) were identified via the 
general practice medical records using a standardised search (Hammersley, Flint et 
al. 2011). Patients who were identified as having a relevant hay fever medication 
then had their medical records checked to ensure that the medication was for hay 
fever rather than another allergic disorder, to exclude any false positives where 
possible. As required by the ethics committee, a member of the practice team also 
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were asked to be as inclusive as possible and to state a reason for exclusion (see 
Appendix 2). 
 
The practices were then asked to write to eligible participants sending an invitation 
letter (see Appendix 3) with a participant information sheet, consent form and patient 
data collection form (see Appendix 4, 5 and 6) and a reply paid envelope for return 
directly to the study team. These letters were signed by either a GP or practice nurse 
and printed on practice letter headed paper. An Excel spreadsheet of eligible patients 
was created and stored on a practice computer, and this was used to identify patients 
who did not respond and therefore needed a reminder. Reminder packs were sent to 
non-responders by the practice nurse two weeks after the initial mailing.  
 
During the planning of the trial consideration was given as to how to engage the 
adolescent participants and maximise compliance with the protocol. The key time 
points for reminders for participants were two weeks following the mailing of the 
questionnaires and the night before the health care professional consultation. 
Previous work has shown that mobile phone short messaging service (SMS) can be 
used effectively in research involving adolescents and that it is feasible and useful as 
a reminder tool (Gurol-Urganci et al. 2013; Balzer et al. 2014). Consenting patients 
were asked to express their preferred method of communication with the research 
team: email, mobile phone short messaging service (SMS) or post and the method of 




3.3.3. Inclusion criteria 
General practices: 
 General practices that were within the recruitment areas of the SPCRN and 
NYREN that agreed to participate in the study  
 General practices that were willing to allow a nominated health care 
professional to attend a one-day training workshop on allergic rhinitis and 
asthma  
Patients: 
 All young people aged 12-18 years with a clinical diagnosis of hay fever 
defined by the presence of a documented clinician diagnosis in their health 
record and/or any evidence of treatment used for hay fever 
 Patients who returned a signed consent form. 
3.3.4. Exclusion criteria 
General practices: 
 General practices not interested in participating  
 General practices unable to release practice staff to attend the training.  
Patients: 
 Patients who were found to be false positives for hay fever on closer 
examination of their medical record   
 Patients who were screened out by appropriate medical staff  
 Patients who did not return the consent form. 
3.4. Randomisation and minimisation 
Randomisation to intervention or control was carried out separately within each of 
the five participating regions: Lothian; Borders; Durham and Tees Valley; 
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Northumberland Tyne and Wear and Yorkshire. For the four regions with more than 
two practices, this was done using a centralised minimization scheme according to 
the methods described by Carter and Hood (Carter et al. 2008) in order to achieve an 
optimum balance for practice list size and deprivation scores (see Appendix 7). The 
randomisation was carried out by a statistician who was independent of the 
recruitment of clusters and patients. 
 
The reason for randomisation by centre was to help ensure an even distribution of 
intervention and control practices as there was likely to be a geographical variation in 
pollen counts between centres. In order to minimise selection bias, practices were not 
randomised until all patients had been identified from electronic searches and invited 
by mail to participate.  
3.5. Sample size 
Using data from a parallel group study which used the RQLQ in adults with 
perennial rhinitis (Sheikh, Khan-Wasti et al. 2007), a mixed-model analysis of 
variance (Murray 1998) was calculated in SPSS and gave an F-ratio of less than 
unity, indicating that there was less variation between practices than would be 
expected by chance. This means that the inter-practice variance and hence the ICC 
was estimated as zero, and there would thus be no anticipated DE for the proposed 
cluster RCT. There are obvious differences between the study in adults and this 
cluster trial in adolescents, including the trial design. An ICC of 0.02 was therefore 
chosen based on a range of ICCs reported in previous work in primary care 




In order to determine the potential cluster size for the trial, two general practice 
databases were searched using a standard search strategy (Hammersley, Flint et al. 
2011). This search suggested that between 19 and 36 patients would be eligible based 
on these two practices with relatively small list sizes (5196, 6376 respectively). A 
cluster size of 10 was chosen based on these numbers, in the hope that it would be 
possible to recruit at least this number of adolescents with diagnosed current hay 
fever from most general practices. 
 
Taking account of the cluster design, using a standard deviation of 1.2 (Juniper, 
Thompson et al. 2002) with a power of 80% to detect a minimal clinically important 
difference of 0.5 (Juniper, Guyatt et al. 1994) in RQLQ(S) score at a significance 
level of 5%, an estimate of the cluster size of 10 and an ICC of 0.02 required a total 
of 22 clusters and an adjusted sample size of 220 patients (unadjusted 180). 
Sampsize was used for sample size calculations (Campbell et al. 2004). 
 
Based on these figures, at least 22 general practices were required to recruit 10 
patients each. Assuming that there would be some loss to follow-up, this patient 
number was inflated by 20% resulting in 22 clusters recruiting 12 patients per 
practice, giving a total of 264 patients in the study (i.e. 132 per arm). With these 
numbers, the study was sufficiently powered (80%) for the primary outcome 
measure. 
3.6. Intervention arm 
The intervention was in two phases: the first phase was at the level of the 




Figure 3.2: Pictorial representation of the process for this intervention 
 
(HCP –Health care professional) 
3.6.1. Educational intervention  
Nominated health care professionals allocated to the intervention arm were invited to 
attend a one day intensive short course ‘Essentials of Allergic Rhinitis’ (and its 
impact on Asthma) run by Education for Health, a charity which focuses on the 
education of health professionals with the aim of improving patient health and 
quality of life. In seeking to mirror the ways in which the majority of UK health care 
professionals receive their continuing professional education, an intensive, evidence-
based one day course was developed by Education for Health from a diploma level 
allergy course. This course provided a basic understanding of allergic rhinitis and 
related conditions including asthma, and aimed to equip health care professionals 
with the knowledge, skills and expertise to support adolescents to optimally manage 
their hay fever. For the purposes of the trial, the short course was adapted to increase 
its salience to the management of hay fever in adolescents.  This adaptation was 
undertaken by Education for Health’s course development staff in conjunction with 
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The interactive course began with an assessment of the participant’s current allergy 
knowledge, followed by the presentation of a case study of a child with a history of 
infantile atopic eczema/dermatitis, from a smoking family, history of parental asthma 
and who have three pets. The delegates were asked to consider the question: 
‘What would make you suspect a diagnosis of allergic airways disease in this 
child?’, which led on to a discussion about the importance of getting the diagnosis of 
allergy correct, focussing on history taking including family history and treatments 
prescribed as well as the impact any symptoms could be having on the child’s QoL. 
This case study was referred to throughout the whole training day to reinforce key 
learning points and consider the progress of allergic disease throughout childhood 
and adolescence. 
 
The second session gave a brief overview of the pathophysiology of allergy 
including classification of allergy, before moving into a more detailed discussion of 
this in the context of hay fever. Making a diagnosis from history taking and 
examination was followed by a description of methods used to confirm a diagnosis, 
such as SPT for common aeroallergens such as mixed grass and tree pollen, and tests 
for specific IgE. Delegates were then given a very brief overview of food allergy and 
atopic eczema/dermatitis.  
 
Session 3 of the day focussed on the management of allergic airways, and considered 
allergic rhinitis as a risk factor for asthma as well as a disease causing considerable 
morbidity in its own right. Evidence from a case-control study on the impact of hay 
fever on examination performance (Walker, Khan-Wasti et al. 2007) was presented 
and discussed. Delegates were given a copy of the British Society for Allergy and 
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Clinical Immunology (BSACI) allergic rhinitis algorithm (Scadding, Durham et al. 
2008), and all treatment discussions were based on ARIA (Bousquet, Khaltaev et al. 
2008) and the British Guideline on the Management of Asthma (British Thoracic 
Society/Scottish Intercollegiate Guidelines Network 2008) for the management of 
allergic rhinitis and asthma respectively which were current at the time of the study. 
It was felt by the trainers and the research team that it would be important for the 
health care professionals to have a good understanding of management of asthma as 
well as allergic rhinitis for two reasons: firstly the total steroid dose for hay fever 
sufferers with comorbid asthma was discussed for patients who may be prescribed a 
nasal steroid, and secondly, it was suggested that including strategies for managing 
patient’s hay fever in a patients annual asthma review may be opportunistic, but 
beneficial in terms of treatment for both diseases.  
 
Embedded within the short course were practical sessions on nasal spray and inhaler 
device technique. There was ample time for individual and group discussions to 
ensure that individual learning styles were met and any queries were addressed. The 
final session asked delegates to consider the question: ‘What are you going to do 
when you return to your practice?’ 
 
Delegates were prompted to think about how they might raise awareness of the 
impact of poorly treated hay fever in their patients, particularly adolescents; whether 
changes could be made to improve Read coding to ensure patients with disease can 
be accurately identified; to consider what advice they would give to patients with 
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allergic disease and how they might put into practice tomorrow what they have 
learned today. 
 
The course was delivered twice in the spring of each trial year prior to the hay fever 
season by Education for Health trainers. 
3.6.2. Patient appointments with health care professionals 
Practices were asked to allocate clinic times for the nominated health care 
professionals to see patients. Patients were informed to contact their practice to book 
an appointment convenient to them. Appointments were between 10 and 15 minutes, 
depending on the practice policy. Contact was made with the practice to ensure that 
all consenting patients had made an appointment during May-June 2009 and May-
June 2010. 
 
No guidance was given to either arm about the format of the consultation; however 
some health care professionals in the control arm did request help. All patients were 
reminded via their chosen method of communication 24 hours prior to clinic 
appointment. 
3.7. Control arm 
Health care professionals in the control arm were provided with a copy of the BSACI 
guidelines for the management of allergic and non-allergic rhinitis (Scadding, 
Durham et al. 2008) (see Appendix 8).  
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3.8. Outcome measures 
3.8.1. Primary outcome 
The primary outcome was: 
 The changes in RQLQ(S) score between baseline and 6-8 weeks post-
intervention in the control and intervention arms (see Appendix 9 for 
RQLQ(S)). 
3.8.2. Secondary outcomes 
The secondary outcomes were: 
 Patient reported symptom scores using a visual analogue scale 
Patients were asked to indicate their overall hay fever symptoms as a visual analogue 
score (scale 0-10) in response to the question: ‘How has your hay fever been this 
week?’ (see Appendix 10 for visual analogue scale). 
 Number of consultations for hay fever, number of prescribed medication 
The total number of consultations with reasons and prescriptions between the date 
the patient was seen for the trial and the end of August 2009/10 were extracted from 
their medical records. 
 Assessment of change in clinical practice in the intervention arm 
Health care professionals in the intervention arm completed a questionnaire at three 
time points: immediately prior to the training intervention, immediately post-training 
intervention and, after they had seen all the patients in the trial. This questionnaire 
measured the effects of the training on skills and confidence following the training 




3.9. Data collection 
3.9.1. Cluster characteristics 
Baseline data collection for clusters included deprivation scores (SIMD and IMD 
2004) which were obtained from the Information Services Division (ISD) of NHS 
National Services Scotland (http://www.isdscotland.org/) for the Scottish clusters 
and the Office of the Deputy Prime Minister website (www.odpm.gov.uk) for the 
English clusters. List size was obtained from ISD for Scottish clusters and from the 
practice managers for the English clusters. 
3.9.2. Baseline patient data 
Consenting patients were asked to complete a baseline data collection form which 
included basic demographics such as date of birth and sex as well as information 
about the duration of their hay fever and current medication. Primary and secondary 
patient reported outcomes were measured at the beginning of the hay fever season 
prior to the clinic appointment. Patients were reminded to complete their baseline 
RQLQ(S) and symptom score by email, SMS or telephone call to ensure they were 
returned prior to their clinic appointment. Practice nurses were requested to check 
that every patient had completed the baseline questionnaires at the beginning of the 
appointment. To maximise completion rates, if the patient had not completed the 
baseline questionnaire, copies were given to the patient for self-completion before 
the consultation started. 
3.9.3. Process data 
Consultation and prescribing data were collected from the general practices for all 
patients from the date of consultation for the study to the 31
st
 August 2009 or 2010. 
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For each patient, every consultation with reason and every prescription within the 
above timeframe was recorded. Numbers were totalled for the following categories: 
 number of consultations 
 number of consultations for hay fever 
 number of consultations for other respiratory conditions 
 number of prescriptions 
 number of prescriptions for hay fever 
3.9.4. Follow-up 6-8 week questionnaires 
RQLQ(S) and a visual analogue scale for recording symptoms scores along with 
reply-paid envelopes were sent to each patient within 6 weeks of their health care 
professional consultation, which covered a period of predicted peak pollen counts 
based on pollen data from previous years. Reminders to complete and return the 
questionnaires were sent by SMS, post or email. A second set of questionnaires with 
reply envelopes were sent to non-responders two weeks after the initial mailing. 
3.9.5. Pollen data 
In order to assess whether the pollen count reached a level which may induce hay 
fever symptoms during the study period, and when that potential peak happened in 
relation to the patient data collection for primary and secondary outcomes, pollen 
data were collected. Grass pollen data were available for the 2009 and 2010 
seasons in two sites: Edinburgh and York. Data from Newcastle were not available 
for these two years, however data were provided for 2007 and 2008. The pollen 
count is a measure of the number of pollen grains of a certain type per cubic metre 
(pgm
3
) of air sampled, averaged over 24 hours. The pollen forecast is usually given 
as low (<30 pgm
3
), moderate (30-49 pgm
3
), high (50-149 pgm
3





). Most sufferers will start to experience symptoms when the count 
reaches the moderate category. Data were obtained from NPARU at the University 
of Worcester, as well as directly from researchers based in Edinburgh and York. 
3.10. Missing data 
The RQLQ(S) is divided into seven domains with varying numbers of questions per 
domain. The overall RQLQ(S) score is calculated from the mean of each domain. 
Where responses to a whole domain were missing, the patient was excluded from the 
analysis.  
 
An intention-to-treat analysis was proposed on all those with only baseline RQLQ(S) 
using the last observation carried forward, but this was not appropriate as imputing 
of the baseline data (which was collected before the pollen season) for subjects 
whose final RQLQ(S) were missing would not be conservative, since the lack of 
change from a value measured before the hay fever season might be better than 
expected (i.e. baseline values may be low on  a scale of 0-6, where 0 is not troubled 
and 6 is extremely troubled). Imputing this data for an RQLQ(S) measured at the 
peak of the season, which may have been high, might result in over-estimation of the 
intervention effect if more cases had missing data in the intervention arm. A 
complete case analysis provided unbiased estimates under the assumption that the 
missing data are ‘Missing Completely at Random’ (Rubin 1976), however a 
preliminary analysis of the means estimated for each pattern of missingness 
suggested that this assumption may not hold. Further sensitivity analysis based on the 
following assumptions was therefore carried out: 
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 The direct likelihood method (Molenberghs et al. 2007): The primary analysis 
of the effect of the intervention on RQLQ(S) was repeated, but with the 
baseline score modelled jointly with the outcome at six weeks instead of 
entering the model through the linear predictor. Using this model allowed for 
the inclusion of all 309 patients with data on at least one occasion and 
provided likelihood estimates that are valid under the MAR assumption 
(Rubin 1976). 
 Multiple Imputation: Proc MI in SAS was used to generate multiple 
imputations (m=100 imputations) separately for each treatment arm (pooling 
across centres). 
 Alternative sensitivity analysis under MNAR: Sensitivity analyses under a 
MNAR assumption were carried out based on two assumptions: 1. that 
missing values in any particular cluster (at baseline or follow-up) were equal 
to the largest observed score from that cluster (and time point) (poor 
outcome), and 2. that missing values in any particular cluster (at baseline or 
follow-up) were equal to the lowest observed scores from each cluster (and 
time point) (good outcome) to impute missing values. 
 
3.11. Data analysis  
All data were double entered by two independent people, and checked for errors 
using SPSS (version 14, 2005). Discrepancies identified were checked from the 
original source and amended, and the data were checked again until no discrepancies 
were identified.  
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3.11.1. Cluster characteristics 
Data were compared for list size and deprivation scores between participating (n=38) 
and non-participating practices (n=204), and intervention (n=20) and control 
practices (n=18) using two sample t-tests in SPSS (version 14, 2005).  
3.11.2. Patient characteristics 
Patients in the intervention and control arms were compared for age and sex. 
3.11.3. Primary outcome 
Complete case analysis was undertaken. In the analysis of RQLQ(S), multi-level 
modelling using a random effects model (MLWin (version 2.20, 2010)) was used 
to take account of between and within cluster variation, adjusting for baseline 
score, strata, individual covariates and year of study. Estimates and confidence 
intervals of the intervention effects were calculated for the RQLQ(S). Patterns of 
missing data at the two data collection time points and between the intervention 
and control arms were explored. 
3.11.4.  Secondary outcomes 
In the analysis of symptom score, multi-level modelling using a random effects 
model was used to take account of between and within cluster variation, adjusting 
for baseline score, strata, individual covariates and year of study. Estimates and 
confidence intervals of the intervention effects were calculated for the symptom 
score. 
 
Differences between the two arms for the process measures of number of 
consultations and prescribing data were analysed using multilevel analysis in 
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MLWin (version 2.20, 2010). Differences in the mean scores of self-reported 
knowledge and confidence in the intervention arm were compared using t statistics.  
3.11.5. Estimates of the ICC 
Two alternative approaches were taken to estimate the ICC using RQLQ(S) data 
from the adult perennial allergic rhinitis trial referred to previously (Sheikh, Khan-
Wasti et al. 2007) and this trial of adolescents with hay fever: a mixed-model 
analysis of variance using SPSS (version 14, 2005), and a Bayesian approach (which 
acknowledges that and ICC cannot be negative) using WinBUGS (1.4 2009) using a 
uniform prior of 0-1 (uniform on ICC) (Spiegelhalter 2001). 
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Chapter 4 – Results  
This chapter presents the results of the cluster RCT. Baseline characteristics of the 
general practices (clusters) and the target population of adolescents with a diagnosis 
of hay fever are presented with the flow of clusters and participants through the trial 
following the CONSORT guidelines for cluster trials (Campbell, Piaggio et al. 
2012).  
4.1. Baseline characteristics 
4.1.1. General practices (clusters) 
Thirty eight general practices (clusters) agreed to participate in the study, 20 were 
randomised to the intervention arm and 18 to the control arm. Clusters were 
comparable for baseline characteristics in terms of deprivation; however the 
intervention practices had a larger mean list size (see Table 4.1). No differences were 
found in terms of list size and deprivation between the participating and non-







Table 4.1: Baseline information for each arm at individual and cluster level 
 
 
 Intervention Arm Control Arm 
Practice factors    
Number of clusters 20 18 
Mean list size 11144 8330 
Mean deprivation score   
IMD
1
 21.5 21.7 
SIMD
2
 2.48 2.47 
Participant factors   
Number 223 118 
Mean age (years) (sd) 15 (1.85) 15 (1.91) 
Number (%) male 112 (50.2) 57 (48.3) 
1IMD - The 2004 Index of Multiple Deprivation for English practices  




Table 4.2: Comparison of demographics of participating and non-participating 
practices in England and Scotland 
 
 







Scottish sites (n=7) 
 
   
List size 6562 (3363) 6971 (3302) P=0.75 
SIMD1 2.69 (0.67) 2.60 (0.70) P=0.76 
English sites (n=31) 
 
   
List size 8707 (4048) 7464 (4847) P=0.19 
IMD2 26.8 (18.2) 31.0 (19.6)  P=0.27 
1SIMD - Scottish Index of Multiple Deprivation  
2IMD - The 2004 Index of Multiple Deprivation for English practices  
 
4.1.2. Participants 
Of the patients assessed for eligibility from the general practice medical records, 
1565 satisfied our inclusion criteria and of these 341 (22%) agreed to participate 
(Figure 4.1). Participants were comparable at baseline in terms of age and sex 
profile. 
 
More patients were randomised to the intervention than the control arm (Table 4.1) 
despite the number of clusters in the two arms being comparable. This was due to the 
variability in cluster size between the two arms which is liable to happen by chance 
in a cluster randomised trial; in this trial the three practices with very large cluster 
size were all in the intervention arm.  
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Figure 4.1: CONSORT trial flow diagram. 
  
Invited to participate (n=242) 
(n=242) 
Excluded   
Declined to participate 
(n=204) 
 




Excluded from analysis n=63 (did not 
complete quality of life questionnaire) 
Participants included in analysis n = 160 
 
Lost to follow up: 
0 clusters 
63 (23%) participants did not respond to 
quality of life questionnaire 
Allocated to intervention n=20 
Received allocated intervention  
19 clusters, median cluster size = 10, range 2-40, 
223 participants 
Did not receive allocated intervention: n=1 
Not able to attend educational intervention (1 
cluster) 
 
Lost to follow up: 
0 clusters 
32 (27%) participants did not 
respond to quality of life 
questionnaire 
Allocated to control n=18 
Received allocated intervention  
18 clusters, median cluster size = 7, 
range 1-12 
118 participants 






Excluded from analysis n=32 (did 
not complete quality of life 
questionnaire) 









Figure 4.2 shows the cluster size variation between clusters, for example practice 15 
(control arm) had a large list size and 37 eligible patients, but only five patients 
consented to take part, where-as practice 22 (intervention arm) had 40/108 patients 
consent to take part. Appendix 2 shows the number of patients in each arm who were 
eligible and invited to take part and how many of them actually did.  
 





○ Control arm 
 
● Intervention arm 
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4.2. Primary outcome: RQLQ(S) 
Adjusting for baseline RQLQ(S) in the analysis was based on an assumption that 
patients with a higher baseline RQLQ(S) score will have a higher RQLQ(S) at 
follow-up, which was measured at the peak of the pollen season. Figure 4.3 shows 
that baseline RQLQ(S) was strongly associated with follow-up RQLQ(S). The lines 
cross, which may indicate that at one point the intervention arm was doing worse 
than the control arm, however this was explicable by sampling error. Figure 4.3 
presents unadjusted data and was not the model used in the analysis, it is purely 
indicative evidence for adjusting for baseline RQLQ(S), which was stated in the trial 





Figure 4.3: Association between baseline (RQLQ1) and follow-up (RQLQ2) 





      
 
  









RQLQ 2    
RQLQ1 - Rhinoconjunctivis 
quality of life baseline score  
RQLQ2 - Rhinoconjunctivis 




● Intervention arm 
/ Control arm 
/ Intervention arm 
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Two hundred and forty six out of 341 patients (72%; 50.2% male, mean age 15 
years) provided complete data and were included in the primary outcome analysis. 
The effect of the intervention was to improve RQLQ(S), but not significantly (-0.15, 
95% CI -0.52 to +0.21), meaning that the training had a small non-significant impact 
on disease-specific quality of life after adjusting for baseline RQLQ(S), practice list 
size, region, year of study and deprivation. The improvements in RQLQ(S) detected 
were well short of the minimal clinical important difference (0.5) (Juniper, Guyatt et 
al. 1994).  
 
Repeating the same analysis without adjusting for baseline RQLQ(S) gave more 
patients (n=273), but was still not significant (-0.03, 95%CI -0.35 to +0.42). 
 
Examination of the seven individual domains of the unadjusted RQLQ scores 
shown in Figures 4.4a-g firstly reinforces the fact that participants in this trial had 
mild-moderate hay fever, as no mean RQLQ(S) value was higher than 3.5 out of a 
score range of 0-6 (where 0 = no impairment of RQLQ(S) and 6 = high impairment 
of RQLQ(S)).  
 
Secondly Figures 4.4a-g illustrate little evidence that there is a main effect of the 
intervention, or intervention with baseline RQLQ(S), the lines are not completely 
parallel, however this is explicable by chance. Figures 4.4 a-g show the unadjusted 
individual domain scores of the RQLQ(S), these data have not been subjected to 
multi-level modelling to take account of clustering, but as there was no 
intervention effect multi-level modelling analysis on each domain would not add to 
85 
 
the interpretation of the results. These figures are therefore only illustrative, but 
have the advantage of clearly showing the baseline and post-intervention minimum 
and maximum values of the mean domain scores and the change over time in each 
group. Although there are no apparently important differences between the 
intervention and control arm unadjusted RQLQ(S), it was important to explore 
whether any one domain was more affected by the intervention than another. 
Figure 4.4c and 4.4f show that the intervention arm’s mean score for non-nose/eye 
symptoms and eye symptoms respectively were higher at baseline than the mean of 
the control arm, but at six weeks the two values were the same.  
Figure 4.4a: RQLQ(S) scores recorded at baseline and 6 weeks post intervention 
































Figure 4.4b: RQLQ(S) scores recorded at baseline and 6 weeks post 




Figure 4.4c: RQLQ(S) scores recorded at baseline and 6 weeks post intervention 



























































Figure 4.4d: RQLQ(S) scores recorded at baseline and 6 weeks post 




Figure 4.4e: RQLQ(S) scores recorded at baseline and 6 weeks post 




























































Figure 4.4f: RQLQ(S) scores recorded at baseline and 6 weeks post 





Figure 4.4g: RQLQ(S) scores recorded at baseline and 6 weeks post intervention 



























































4.3. Secondary outcomes 
4.3.1. Symptom scores 
Symptom scores in the intervention arm were slightly lower than the control arm (-
0·24, 95% CI -1.03 to +0.54).  
4.3.2. Consultation and prescribing data 
Five practices out of 38 did not provide data on consultation and prescribing 
patterns (three control and two intervention arm practices). One of these, a control 
practice, was not willing to provide data about consultations and prescriptions not 
related to hay fever and the remaining four did not respond to requests for data. 
There were no significant differences in the total number of consultations, number 
of consultations for allergic rhinitis or other respiratory conditions and total 
number of prescriptions for allergic rhinitis between the two arms (see Table 4.3); 
however the total number of prescriptions differed between the two arms. The 
mean total number of prescriptions per patient was 2.24 in the control arm and 2.89 









 Intervention arm 
(n = 193) 
 
Control arm 









200 85 +0.30  
(-0·02, +0·63) 
Total number of allergic 
rhinitis consultations 
55 29 -0.08  
(-0·24, +0·08) 
Total number of 
consultations for other 
respiratory conditions 
27 8 +0.11  
(-0·01, +0·22) 
Total number of 
prescriptions  
  
557 197 +1.11 
(+0·08, +2·15) 
Total number of 
prescriptions for allergic 
rhinitis 
406 140 +0.01 
(-0·10, +0·12) 
1 from date seen to 31st August 2009 or 2010. 
2
 95% confidence limits for difference in mean between 





4.3.3. Assessment of change in clinical practice 
Health care professionals’ improvement in confidence, understanding and 
management markedly increased post-intervention when compared with the 
baseline assessment (see Table 4.4). All scores improved from Time 1 
(immediately prior to the training day) to both Time 2 (immediately after the 
training day) and Time 3 (after all patients had been seen as part of the study), but 




Table 4.4: Audit of confidence in delivering allergy care (n=21) 






How confident are you at:     
Taking a comprehensive allergy history from a patient with suspected allergy? 2·6 4·2 4·4 1.6 (1·0, 2·2) 
Doing skin prick testing? 1·1 2·7 2·4 1.5 (0·4, 2·6) 
Ordering specific IgE test? 1·5 3·8 3·5 2.0 (1·2, 2·8) 
Making a diagnosis of allergy? 2·1 4·4 4·3 2.2 (1·6, 2·7) 
Explaining the various effective treatment strategies for allergic problems? 2·2 4·3 4·7 2.4 (1·9, 2·9) 
Prescribing/recommending treatment for allergic conditions? 2·3 4·1 4·6 2.1 (1·4, 2·8) 
Teaching patients how to use nasal spray devices? 2·3 4·7 5·0 2.5 (1·9, 3·2) 
Explaining the causes and mechanisms of allergy? 2·4 4·2 4·5 2.1 (1·4, 2·7) 
Understanding the impact of allergy on morbidity and mortality? 2·6 4·2 4·5 2.1 (1·4, 2·7) 
How likely are you to do the following:     
Ask about other allergic symptoms (e.g. nose/skin) when assessing a patient with asthma? 3·3 4·8 4·8 1.3 (0·6, 2·0) 
Consider total steroid use in patients on multiple therapies? 2·6 4·2 4·1 1.6 (1·0, 2·2) 
Offer practical advice on avoiding allergens? 3·1 4·8 4·9 1.7 (1·0, 2·4) 
Suggest patients use their nasal steroids regularly? 3·1 4·9 5·0 1.9 (1·3, 2·5) 
*Time 1 – immediately prior to the training day, Time 2 – immediately after the training day, Time 3 – after all patients had been seen as part of the study (range 7-28 
days). 
1
 95% confidence limits for change in mean score from time1 to time 3 
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4.3.4. Timing of primary and secondary outcome and grass pollen data 
Grass pollen data were collected from two sites for 2009 and 2010. Figure 4.5 
indicates that the grass pollen reached high levels (50-149 pgm
3
) at both sites in both 
years. The protocol timeframe for data collection aimed for baseline RQLQ(S) and 
symptom scores in March 2009/2010, patients to be seen by their health care 
professional in May/June 2009/2010, and follow-up RQLQ(S) and symptom scores 
to be recorded in July/August 2009/2010 (Hammersley, Elton et al. 2010). Figure 4.6 
shows the actual data collection timing in relation to the pollen count, and it can be 
seen that the timing of the baseline data collection slipped, with the majority of 
baseline RQLQ(S) and symptom score data in year one (RQLQ1 2009) being 
collected in May 2009, and a small number were not collected until June 2009. 






















































Notes: The pollen forecast is usually given as low (<30 pgm
3





) or very high (≥150 pgm
3
).  
RQLQ1 – Standardised Rhinoconjunctivitis Quality of Life Questionnaire at baseline 


































































4.3.5. ICC estimates 
As discussed above, the estimate of the ICC in the adult study (Sheikh, Khan-Wasti 
et al. 2007) was negative (Table 4.5), and an F ratio of less than unity indicated that 
there was potentially less variation between practices than would be expected by 
chance. The estimates for ICC in this study using both methods described in Section 
3.10.5 are shown in Table 4.5.  
 
Table 4.5: ICC estimates using alternative approaches in two studies 
 
 Mixed-model  
CI for ICC 95% 
 




-0.143 to +0.012 0.002 to 0.0201 
Adolescent study 
 
-0.02 to +0.25 0.0016 to 0.145 
 
4.4. Missing data 
4.4.1. Patterns of missingness for the primary outcome RQLQ(S) 
341 patients were allocated to either the intervention or control arm of whom 309 
patients contributed with data on at least one occasion (baseline or follow-up or 
both). 282 patients had a baseline measurement, 273 patients had a measurement at 
six months follow-up and 246 patients had complete data at both time points. 
Patients in the intervention arm with some missing data had higher scores on the 
occasions when they are observed (Table 4.6a). The amount of missing data was 
roughly equal in the two treatment arms. As described in Section 4.9.5, a complete 
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case analysis provides unbiased estimates under the assumption that the missing data 
were missing completely at random, however the means estimated separately for 




 Table 4.6a Patterns of missing data in the intervention arm 
 





Observed-observed 160 1.87 2.66 
Observed-missing 24 1.96 N/A 
Missing-observed 20 N/A 3.04 
Total 204   
 
Table 4.6b Patterns of missing data in the control arm  
 
Pattern n Mean at 
baseline 
Mean at follow 
up 
Observed-observed 86 1.80 2.68 
Observed-missing 12 2.34 N/A 
Missing-observed 7 N/A 1.93 
Total 105   
 
Table 4.6c Patterns of missing data combined 
 
Pattern n Mean at 
baseline 
Mean at follow 
up 
Observed-observed 246 1.85 2.67 
Observed-missing 36 2.08 N/A 
Missing-observed 27 N/A 2.75 






Using the direct likelihood approach (Molenberghs and Kenward 2007), the 
estimated (adjusted) effect of the intervention on the outcome was 0.031 (s.e. 0.185; 
95% CI: -0.33 to 0.39), compared with the primary analysis based on the complete 
cases: estimates effect: -0.154 (s.e. 0.182; 95% CI:-0.52 to 0.21). The overall mean 
effect of the intervention was estimated to be 0.058 (s.e. 0.185; 95% CI: -0.30 to 
0.42). The two approaches to sensitivity analyses gave estimate effects of 0.212; (s.e. 
0.214; 95% CI: -0.210 to 0.633) (poor outcome) and 0.025; (s.e. 0.209; 95% CI: -
0.39 to 0.44) (good outcome). 
  
Summary 
Despite an improvement in the knowledge and understanding in the health care 
professionals which was sustained over the short-to-medium term, this did not result 
in a change in patient outcomes, evidenced by no difference between the two arms in 
prescribing for allergic rhinitis. The results of the cluster RCT have been reported in 
keeping with the CONSORT guidelines (Campbell, Piaggio et al. 2012), and are 
described in terms of clusters and patients, primary and secondary outcomes, process 
measures which will allow the effect of the intervention, or lack of effect to be 
explored, and ICC estimates are reported which will give helpful context to any 
future trials of educational interventions in primary care. 
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Chapter 5 - Discussion 
This chapter will firstly consider the strengths and limitations of the trial undertaken 
and seek to interpret the findings of this work in the context of the wider literature of 
educational interventions in primary care, and secondly, present the conclusions and 
reflect on the implications for future work. 
5.1. Statement of principal findings 
This large primary care-based cluster RCT has shown that a short intensive 
evidence-based allergy workshop for health professionals led to substantial and 
short-medium term improvements in professionals’ self-reported confidence and 
understanding of the management of hay fever. Despite this, it did not translate into 
changes in clinical practice in terms of frequency of consultations or prescribing 
habits. Most importantly, this did not lead to clinically significant improvements in 
disease-specific QoL or symptom scores in adolescents with hay fever.   
5.2. Strengths and limitations of the evaluation 
Educational interventions aimed at improving health care professionals’ knowledge 
and changing patient’s health outcomes should be evaluated for effectiveness and 
reported in the same way as any other intervention (Medical Research Council 
2000; Campbell, Elbourne et al. 2004). 
5.2.1. Strengths of the evaluation 
The main strength of this trial was the decision formally to evaluate this evidence-
based complex educational intervention using an adequately powered cluster RCT. A 
parallel group trial would have been inappropriate due the risk of contamination 
between patients randomised in the same practice. The use of cluster trials for 
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educational interventions in health care settings such as primary care is widely 
recommended (Eldridge and Kerry 2012). An important related strength of this trial 
was reaching the sample size required in terms of number of clusters and patients, 
which was made difficult in the first year due to low numbers of practices 
volunteering for the trial. By extending the trial to English sites and recruiting for a 
further year, adequate power was achieved (Hammersley, Elton et al. 2010), which is 
particularly important in the context of negative trials in order to minimise the risk of 
Type II errors (Kirkwood et al. 2003). Further explanation of the power calculations 
and the decision to continue into a second year of recruitment are described in 
Appendix 11.  
 
The educational intervention evaluated in this trial was an adapted one-day short 
course which was regularly delivered by Education for Health for training health care 
professionals in primary care. The developmental work for the short course had 
already been completed by educationist/health care professionals at Education for 
Health during the development of the modules for the Diploma in Allergy. The 
allergy module was evaluated in the parallel group trial previously described 
(Sheikh, Khan-Wasti et al. 2007), and measured the effectiveness of this on a 
validated disease-specific quality of life measure (Juniper, Thompson et al. 1999). 
This was in keeping with the MRC’s complex intervention framework (Craig, 
Dieppe et al. 2008). The educational intervention was modified a number of times in 
consultation with expert educationists using the best evidence available at the time 




A range of relevant process measures, which aimed to shed light on the relevant 
mechanisms through which any changes were mediated and/or blocked, were chosen. 
Nested process evaluations can also provide insight into why a successful 
intervention works or can be optimised (Craig, Dieppe et al. 2008). Despite the 
acceptability of the intervention and its impact on professionals’ self-assessed 
confidence and knowledge of hay fever management, the intervention appeared not 
to equip individuals with the ability to enact relevant structural changes in their 
practices to translate this into improvements in care processes. 
 
Before an intervention can be utilised in routine care the strength of the evidence 
and its internal and external validity should be considered (Eldridge et al. 2008). 
Internal validity refers to the consideration of whether the observed effect of the 
intervention is actually due to the intervention itself and not due to the 
characteristics of the participants recruited to each arm or the way the outcome was 
measured (Eldridge and Kerry 2012). A well designed and conducted, blinded RCT 
of sufficient size should have high internal validity. Selection bias can occur if the 
people recruiting participants are aware of the participants allocation (Eldridge et 
al. 2009), as there is a chance that participants with a particular characteristic will 
be selected for recruitment; for example, in this trial participants in the intervention 
arm may have been selected on the basis of more severe hay fever compared with 
participants in the control sites, and this would obviously impact on the 
intervention effect and introduce bias. This trial was designed so that participants 
were identified and invited to take part before the cluster was randomised, which is 
quite straightforward for trials of management of chronic disease where searches of 
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the electronic record can be used to identify eligible participants, thus reducing the 
risk of selection bias. The consideration of selection bias contributes to the internal 
validity of the trial (Eldridge, Ashby et al. 2008). Recruitment of clusters in this 
trial was more pragmatic and as this group of general practices were self-selected 
in that they volunteered to take part and all were included, this may have affected 
the internal validity of the trial. Other measures of internal validity considered in 
this trial were: the effect of clustering in the sample size calculation and in the 
analysis; blinding of individual participants to allocation status and assessment of 
the primary outcome blind to allocation status (Eldridge, Ashby et al. 2008). 
Blinding of participants to allocation status raises an ethical issue with this cluster 
trial; it could be argued that fully informed consent is compromised by with-
holding allocation status from the participants, however Hutton (Hutton 2001) 
argues that one seeks consent to be in an experiment, not to consent to a particular 
treatment. The ethical and practical considerations of cluster trials create a tension 
which can only be judged on an individual basis. In this trial patients were unaware 
whether they were seeing a trained or untrained health care professional, but were 
able to opt out of the appointment and not complete the questionnaires as with any 
study. 
 
Factors which affect the external validity of the study are whether there is a 
difference between the trial participants and the general population to which the 
results may be applied, or, between the intervention and how it was delivered in the 
trial and how it may be delivered in a routine setting (Eldridge and Kerry 2012). 
Again this can be influenced by good trial design - inclusion criteria for both 
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clusters and participants should not be limiting and exclusion criteria should be 
kept to a minimum. The inclusion and exclusion criteria (see Sections 4.5.3 and 
4.5.4) were kept as simple as possible, however a general practitioner or practice 
nurse in each practice did screen the list of eligible participants prior to letters 
being sent, and the reasons for any exclusions were recorded (Appendix 2).  
 
The trial was conducted under the supervision of an Independent Trial Steering 
Committee (Appendix 12) and conformed to the CONSORT checklist (Appendix 
13). A detailed protocol which included a detailed analysis plan was developed and 
published (Hammersley, Elton et al. 2010) (see Appendix 14).   
5.2.2. Limitations of the evaluation 
Difficulties in recruitment of general practices to this cluster trial resulted in 
extended recruitment involving two cohorts of patients over two years. This 
introduced a variation in pollen count between the two years (see Figure 4.5, Section 
4.3.4). Pollen counting was based on the available two sites: one in Edinburgh and 
one in mid-Yorkshire.  The clusters were however distributed throughout Edinburgh, 
Borders and the north of England; these were therefore only proxy measures for 
pollen. The pollen counts were broadly similar in the two regions and reached a level 
which should have triggered hay fever symptoms in both years. In the multi-level 
modelling analysis of final RQLQ(S) adjusting for list size, area, year, baseline 
RQLQ(S), deprivation and intervention there was a highly significant year effect, 
indicating that the second year cohort of adolescents were more affected than the first 
year cohort. Figures 3.1 and Figure 4.6 shows the impact of recruitment difficulties 
on the timing of the data collection. Practice recruitment was staggered which 
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impacted when patients were invited/recruited/provided baseline data. Baseline QoL 
scores as seen in Figures 4.4a-g do not start at zero, however because of the 
association between baseline RQLQ(S) and follow-up RQLQ(S) shown in Figure 
4.3, analysis was adjusted for baseline RQLQ(S). 
 
The difficulty in recruitment of practices and the resulting loss of power for the trial 
are shown in Appendix 11. After the first year of recruitment follow-up primary 
outcome data were available from 180 patients in 23 clusters, however only 156 
patients in 21 clusters returned both baseline and follow-up outcome data. Based on 
this evidence the following options were discussed with the Trial Steering 
Committee: 
 Proceed with two analyses with the data already obtained:  
o 180 patients with final RQLQ (i.e. no adjustment for baseline RQLQ) 
o 156 patients with baseline and final RQLQ 
 Do no analysis and repeat the study in 2010 to obtain sufficient numbers for 
at least 80% power. 
 Carry out an interim analysis with a priori intervention effect levels to 
determine whether to proceed to further recruitment. 
Deviations from a trial protocol have to be justified and extending the study into a 
further year had implications in terms of financial resources, variation in pollen 
patterns in the second year and its subsequent impact of hay fever and ability to 
recruit clusters and patients which had proved difficult in the first year. However this 
had to be considered against reporting the results of a complex educational 
intervention which would be underpowered and therefore difficult to interpret. The 
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Trial Steering Committee recommended proceeding for a further year despite the 
financial implications and possible variation in pollen patterns in order to report a 
fully powered cluster trial. The additional costs associated with extending for a 
further year were met by two grants I was able to secure from GlaxoSmithKline and 
The University of Edinburgh. 
 
 
Figure 4.2 in Chapter 4 shows the extent of the imbalance in the cluster size – more 
practices in the intervention arm had larger cluster size, which impacted on the total 
number of patients in each arm; this resulted in almost twice as many patients in the 
intervention arm than the control arm despite the attempts to achieve balance through 
stratifying by list size. The power for the trial was calculated taking into account the 
clustered nature of the study, which has the effect of inflating the variance of 
estimates of intervention effects by the design effect (see Section 2.5.2). The formula 
used for calculating the design effect in a cluster RCT assumes that the clusters will 
be of equal size and if they are not then there is a loss of power (Eldridge et al. 
2006). Methods are described to take into account the potential for unequal cluster 
size (Eldridge, Ashby et al. 2006), however variability was not anticipated and 
therefore no adjustment to the trial power was made. In hindsight, a more suitable 
stratification would have been by eligible adolescents with hay fever, or at least 
adolescents registered rather than total list size. The impact on the power of this 
imbalance was modest, and outweighed by the larger than required number of 




The ICC estimate used in the sample size calculation was 0.02, which is a relatively 
low value based on the finding that there was no evidence of significant between-
cluster variation in the previously discussed adult trial (Sheikh, Khan-Wasti et al. 
2007). The larger the value of ICC the greater the loss of power due to the cluster 
design. Estimates of ICCs in educational interventions in primary care are 
infrequently reported, ICCs of other primary care interventions such as obesity 
management education (Moore, Summerbell et al. 2003) are generally around 0.05.  
We were able to report ICCs using two approaches: a mixed model analysis of 
variance and Bayesian approach (see Section 4.3.5). The Bayesian method, which 
makes explicit quantitative use of external evidence for analysis (Spiegelhalter et al. 
2000) guarantees an estimate for ICC of between 0 and 1. Despite the adequate 
sample size in this trial, the confidence limits were quite wide (see Table 4.5), which 
makes it difficult to predict the ICC value with any certainty for future studies. 
Cluster trials should always quote confidence limits for ICCs rather than just 
estimates (Turner et al. 2006), and even with the confidence limits, this may cause 
some difficulty in planning further studies, because sample size estimates depend on 
assumptions about the magnitude of ICC that cannot always be made with any 
certainty.  
 
Simple and multiple imputation methods have been described in relation to QoL data 
(Fielding, Fayers et al. 2008; Sterne, White et al. 2009; Wang et al. 2009) and 
considered in relation to complete case analysis bias, which was the chosen method 
of analysis in this study. The justification for complete case analysis was based on 
the power required for the trial being achieved. Only 246/341 patients were included 
in the complete case analysis, which represents a substantial loss to follow-up. A 
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post-hoc sensitivity analysis was therefore undertaken. This was however a deviation 
from the analysis plan described in the protocol, which can affect the integrity of the 
results of RCTs. Despite this, when taking account of the missing data under a MAR 
assumption (see Section 4.4) there is still no evidence of a beneficial effect of 
treatment on the outcome variable RQLQ (S). This finding was confirmed in the two 
alternative scenario analyses: (1) assuming that patients with missing data have very 
poor outcomes; and (2) assuming that patients with missing data have very good 
outcomes. 
 
A further limitation of this study may be that patients in the control arm of the 
cluster RCT consulted with a health care professional. It was necessary to design 
the study this way in order to understand the cause of any potential effectiveness of 
the educational intervention and to be able to distinguish this from any impact of 
simply being seen by a health care professional for hay fever. Control arm practices 
received an algorithm for the management of hay fever produced by Education for 
Health. One way of disentangling this issue would have been to include a third arm 
in which practices received no intervention, however this was not possible because 
of time and resource constraints.  
 
Consideration should be given to the cost-effectiveness of any intervention as this is 
important for decision-makers in the health service. In a review of 51 educational 
interventions in primary care, only two gave any approximate costs for their 
intervention (Freudenstein and Howe 1999). Actual costs for the trial are detailed in 
Appendix 15. The cost of running the trial per practice in Scotland was £390, and in 
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England £539, this cost was met by Health Boards and PCTs in each area from 
service support budgets and paid directly to each practice. The total cost for the 38 
practices was £19439. This covered all the costs incurred in considering the trial, 
running the trial in each practice, attendance at the one day training and seeing the 
patients once in clinic. The training days themselves cost £4790, giving a total 
estimate of the cost of the trial of £24229. Per practice total cost was approximately 
£637. This does not include any researcher costs. These figures give an indication of 
actual costs for running the cluster trial in primary care; however it does not give any 
indication of cost-effectiveness, and comparative data of actual costs rather than 
cost-effectiveness are not reported in the literature. No economic analysis was 
included in this trial, again due to resource and time constraints. This limits the 
usefulness of trial findings for others to consider replication or use of the intervention 
on a wider scale. 
 
There was no qualitative work embedded in this trial, which is becoming 
increasingly common when evaluating complex interventions in order to explore 
causal pathways of the intervention (Cresswell, Sadler et al. 2012). A recent 
successful example of a mixed-method approach is described by Cresswell et al, 
where a large cluster randomised trial of a complex pharmacist intervention was 
complemented by an embedded qualitative inquiry (Cresswell, Sadler et al. 2012). 
This paper supports the value of qualitative evaluation methods in complimenting 
RCTs of complex interventions and may have helped to interpret the negative 
findings of this trial, as the results of qualitative work can give insight into the blocks 
in the intended pathway. Figure 5.1 shows how the intervention was intended to exert 
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its effect on patient outcomes via education of untrained health care professionals. 
The blue squares show the process and the red circles indicate where the intervention 
may have failed to exert its expected effect. The educational intervention had the 
desired effect of improving self-assessed knowledge and confidence of the health 
care professionals; however it is unclear why this did not translate into improved 
outcomes for the patients without interviews with health care professionals or the 
patients.  
 
Despite practices agreeing to take part in the trial, it may be that the trained health 
care professionals were unable to use their knowledge effectively due to time 
pressures in a busy practice, or that they were not encouraged/supported by other 
practice team members. Despite potential problems with building extra clinics into 
an already busy schedule, all patients who completed the baseline data were seen by 
their health care professional, but this does not mean that they complied with the 
recommendations given to them in terms of optimum medication strategies and 
adherence. An additional limitation of the study was therefore the lack of monitoring 
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5.3. Interpretation of the findings 
5.3.1 . Influence of the trainers on the intervention 
Key dimensions of complexity relevant to this trial are behaviours required of those 
delivering and receiving the intervention; specialist trainers experienced in clinical 
practice as well as the delivery of evidence-based practice developed and delivered a 
short intensive course to health care professionals who then went on to see patients 
with hay fever and tried to alter their behaviour in terms of management of their own 
symptoms.  
 
The two trainers were experienced, practicing allergy and respiratory nurses, with 
their own clinical knowledge and experience (Freudenstein and Howe 1999) which 
may have influenced their interpretation of guidelines and existing evidence. Both 
trainers discussed and modified the content of the one day course on a number of 
occasions before it was finalised and delivered, focussing on areas of particular 
importance for adolescent hay fever sufferers, and these repeated discussions 
would hopefully ensure consistent delivery of the materials by both trainers.  
 
5.3.2. Influence of the health care professionals on the intervention 
Practice health care professionals will also bring their own clinical experience and 
knowledge to any research study, and one of the main challenges of an educational 
intervention in any health care setting is to try to change clinical behaviour in-line 
with the best research evidence. The health care professionals were working within 
a local clinical context, where particular prescribing patterns may be enforced, and 
in this particular case where hay fever may not be considered a serious clinical 
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condition, possibly as it is not part of the Quality and Outcomes Framework 
(National Institute for Health and Clinical Excellence). Allergic rhinitis is a 
common co-morbidity in patients with asthma, and if left untreated can lead to poor 
asthma control (Scadding et al. 2012),  a large retrospective cohort study showed 
that asthma patients with allergic rhinitis had more visits to their GP and were 
significantly more likely to be hospitalised compared with asthma patients without 
allergic rhinitis (Price et al. 2005). Subsequently the ARIA guidelines recommend 
that people with asthma are assessed for allergic rhinitis and vice versa (World 
Health Organization Initiative, Bousquet J et al. 2001). The NICE Quality Standard 
5 (National Institute for Health and Clinical Excellence 2013) for asthma does 
include assessment of co-morbidities for adults, although allergic rhinitis is not 
specified. A systematic review of educational meetings, which includes short 
courses, found that the impact of such educational interventions may be smaller for 
outcomes that health professionals may perceive as not having serious 
consequences for the patient (Forsetlund et al. 2009).  
 
The development-evaluation-implementation process proposed in the MRC 
guidance on complex interventions (Craig, Dieppe et al. 2008) includes identifying 
the existing evidence and a feasibility/piloting stage. When considering the use of 
the short course as the educational intervention for the trial, a limitation was the 
lack of consultation with health care professionals about how it might be most 
effectively delivered in terms of preferences for style of delivery such as 
workshops with interaction, educational outreach visits or audit and feedback 
(Thomson 1998). A systematic review of studies of interventions to improve 
114 
 
delivery of health care systems showed that dissemination activities alone resulted 
in little or no change in behaviour, however more complex interventions only 
produced moderate effects, and suggests that a range of interventions could lead to 
provider behaviour change (Oxman, Thomson et al. 1995; Forsetlund, Bjørndal et 
al. 2009). The MRC complex intervention guidance (Craig, Dieppe et al. 2008) 
suggests that it is crucial to develop a theoretical understanding of the likely 
process of change, and although the educational intervention was modified from a 
previously successful model (which was developed in consultation and 
collaboration with multi-professional stakeholders at the time), consultation with 
‘stakeholders’, in this case the primary health care professionals targeted by the 
intervention may have been beneficial. In a survey of current allergy provisions 
and training (Levy et al. 2004), GPs expressed their preferred training option which 
included day long evidence-based taught courses. Exploration of practical barriers 
to implementing the guidelines introduced in the intervention could have been 
explored with health care professionals in a focus group setting and then suggestion 
of how to effectively address these included in the course. Training only one 
member of a large team of health care professionals may not be sufficient to 
influence any managerial or policy structures that may be in place and in addition 
to the one day course a dissemination event for the whole practice may have 
supported the intervention.  
5.3.3. Influence of the patients on the intervention  
Patients in this study had on average relatively mild impairment of QoL measured 
by the RQLQ(S), which is in line with a similar study exploring quality of life of 
perennial rhinitis sufferers (Sheikh, Khan-Wasti et al. 2007). Patients were 
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recruited from a primary care setting, using a clinician diagnosis of hay fever or a 
prescription for drugs used in nasal allergy in the last two years, rather than 
objective evidence of moderate or severe disease. As also observed in the perennial 
rhinitis trial (Sheikh, Khan-Wasti et al. 2007), the impact of this training 
intervention may have been more evident if trial entry had been restricted to those 
with more severe disease. This would however have reduced the generalisability of 
the intervention to everyday general practice.  
 
The adult trial showed a modest improvement in disease-specific quality of life 
among patients with perennial rhinitis compared with usual care (Sheikh, Khan-
Wasti et al. 2007). Differences between the one day intensive course used in this trial 
and adult diploma study are likely to relate to sustained effort and the incentive of 
succeeding in a final exam than necessarily the content of the day. Short courses are 
popular, they are easily accessed with relatively little burden on the practice in terms 
of time out of clinical practice and they represent the preferred mode of continuing 
professional development in some groups (Thomson 1998). They may serve to 
signpost people to best practice, but not necessarily inform people enough to make 
changes to their clinical practice, and may highlight education need, and provide 
opportunities for networking, meeting experts and bringing people together.  
 
If the training workshop had achieved a sustained change in clinical practice there 
would have been more consultations in the intervention arm. This was not evident, 
although patients in the intervention arm did receive more prescriptions compared 
with the control arm. The training days were delivered by practicing health care 
professionals and based on current evidence-based guidelines for the management 
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of hay fever developed by the BSACI (Scadding, Durham et al. 2008). The 
prescribing data collected included all repeat prescriptions; therefore if the 
intervention practices followed the guidance given during the course, patients with 
persistent symptoms should have received an antihistamine, nasal steroid and eye 
drops as appropriate.   
5.4. Conclusions and implications for future work 
In conclusion, this intensive hay fever training course for primary care health care 
professionals was found acceptable and increased self-assessed confidence in 
attendees, but this did not translate into improvements in symptom control or 
quality of life of adolescents with hay fever. Future trials need to build on the 
findings of both this and the adult perennial rhinitis trial (Sheikh, Khan-Wasti et al. 
2007), and find ways of equipping participants of such short courses with the skills 
necessary to bridge the gap between knowledge and day-to-day practice. Such 
evidence is needed to help ensure that the NHS and other health systems 
internationally invest their limited resources in evidence-based education of proven 
effectiveness. 
 
The findings of this cluster trial and the parallel-group adult RCT (Sheikh, Khan-
Wasti et al. 2007) both point to the need for further work in improving the 
knowledge and skills of primary health care professionals. The two varying models 
are extreme: an intensive one day course and a six month diploma course requiring a 
large time commitment to on-line learning and assessment. It could be argued that 
the best educational intervention may lie somewhere between the two models, for 
example blended learning courses, which have become increasingly feasible with 
wider access and greater functionality/versatility offered by the Internet, however 
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further exploratory work is needed before any resource could be put into testing this. 
Systematic reviews of educational interventions are inconclusive, but suggest that a 
blended learning approach may be more effective at changing patient outcomes 
(Grimshaw, Shirran et al. 2001). This needs to be explored with educationists, health 
care professionals and policy makers using qualitative approaches before a new 
model for an educational intervention could be developed. 
 
It would be equally helpful to talk to the target group about the usefulness of 
consultations about the management of their hay fever. It was assumed that an 
educational intervention for health care professionals followed by a consultation was 
acceptable for the adolescents; however other methods of communicating with this 
patient group could be explored, such as reminders about medication and adherence 
use via social media, information about pollen counts direct to mobile phones, and 
this could be explored using discussion forums either in person or again using social 
media. 
 
The guidance for developing and evaluating complex interventions describes a 
cyclical process (Craig, Dieppe et al. 2008), however on reflection only the 
evaluation of this educational intervention followed this guidance. When designing a 
complex intervention such as an educational course, it should be developed to the 
point where it can reasonably expect to have an effect. As we adapted an existing 
course being delivered to health care professionals rather than developing a new 
course, this was not the case. In addition there was no pilot work, on the basis that 
the six month diploma evaluation had been successfully completed in a primary care 
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setting (Sheikh, Khan-Wasti et al. 2007). These assumptions weakened the likelihood 
of the short course impacting patient outcomes. Any future iteration should include 
identifying the evidence base for the likely process of change (Craig, Dieppe et al. 
2008), which as discussed above could include the views of relevant stakeholders 
and exploration of existing literature, as well as qualitative process evaluation to 
explore causal mechanisms and an economic evaluation to aid possible 
implementation. 
 
5.5. Personal reflections and lessons learnt 
I conclude this thesis by offering some personal reflections. With the benefit of 
hindsight I would have approached a number of elements of this trial differently. In 
the very first discussions with the CSO the issue of recruitment in primary care, 
particularly to cluster trials was highlighted. Previous experience of primary care 
research has taught me that personal contacts can go a long way in engaging 
practices in research; however experience from this trial suggests that the subject 
area has to be pertinent and seen to be of clinical importance and in the case of hay 
fever this appeared to be a stumbling block. In discussions with practices during the 
recruitment phase, a number of GPs told me that hay fever in adolescents was not a 
clinically important area for them to focus resources and therefore engage in 
research. This proved a problem when evaluating an educational intervention aimed 
at primary health care professionals. Alternative recruitment approaches could have 
included recruiting pharmacists to attend the training, and adolescents as they present 
for their over the counter medication, this approach was being piloted (Porteous et al. 
2013) at the time of the current trial and the results are awaited. Earlier discussion 
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with a larger number of primary care research networks would have helped with the 
recruitment, the extension into England brought additional costs for the trial, but 
improved recruitment enormously. 
 
No matter how rigorously a trial is designed, if the intervention being evaluated is 
weak, there is unlikely to be an intervention effect detected. This trial aimed to 
evaluate if an ‘off-the-shelf’ one day workshop for health care professionals could 
improve the quality of life of adolescents, and in hindsight this is not the way 
forward. It is a fact that NHS staff attend one-day courses as part of their 
professional development, but this can only be used as a signpost to more intensive 
learning. This trial would have benefitted from greater investment in the 
development of the educational intervention, including qualitative work to explore 
the potential causal pathway of the intervention using the MRC’s complex 
interventions framework (Craig et al. 2008).  
 
The trial would have been strengthened with a health economics arm, as this would 
have contributed to the literature for future educational intervention evaluations. In 
future trials I would engage very early with a health economist to incorporate an 
economic evaluation of the intervention. 
 
In terms of future cluster trials in primary care this trials contributes further evidence 
for ICC assumptions for sample size calculations, which will be useful when 
planning trials in primary care. The recruitment difficulties experienced and 
described will help future planning of trials in terms of practice and participant 
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Appendix 2: Reasons for exclusion from trial 
 








Reminders No. of 
consenters 
1 16  16 15 1 
2 22  22 17 7 
3 66 3 – mental health, 
serious hospital 
controlled, 
terminal illness in 
family 
63 63 10 
4 21  21 18 10 




20 16 6 
6 20  20 16 4 
7 58  58 52 11 
8 34  34 26 12 
9 30  30 30 6 
10 50  50 41 14 
11 30  30 25 7 
12 21 1 – autistic child 20 20 1 
13 56  56 55 7 
14 57  57 56 7 
15 37  37 35 5 
16 26  26 25 2 
17 33  33 31 8 
165 
 
18 64  64 53 12 
19 81 1 – Downs 
syndrome 
80 66 25 
20 31  31 25 8 
21 40  40 0 12 
22 108  108 98 40 
23 18  18 16 3 
24 58  58 49 12 
25 58  58 51 18 
26 60  60 55 12 
27 41  41 38 6 
28 32  32 27 7 
29 39 11 – mental 
health or not 
current SAR as 
determined by 
lead GP 
28 35 9 
30 52  52 49 5 
31 65  65 56 15 
32 19  19 16 4 
33 41  41 37 4 
34 27  27 25 5 
35 46  46 43 11 
36 31  31 29 3 
37 57  57 50 9 
38 16  16 15 3 











Appendix 4: Information sheets 
Participant Information Sheet- Year 1 
 
Information for teenagers & your parents 
or guardians 
 
The Scottish Government, University of Edinburgh, and education charity Education for 
Health are trying to find out if teenage hay fever sufferers are able to control their hay fever 
symptoms better and so improve their quality of life, if they are treated by health 
professionals who have had specific evidence based hay fever training. Or not.   
  
We needed nurses from 27 General Practices to agree to take part. We’ve sent you this 
information because one of them is a nurse from your practice. All 27 are helping us find 
300 teenagers (age 12 – 18 years) who have hay fever to also take part. If we can’t find 300 
teenagers then we can’t do the research. This sheet explains more about the research and 
what it means to take part. If you’d like even more information or have any questions which 
are not covered here, call Vicky Hammersley on 0131 6503234/07969 775912 or you can 
email her at vicky.hammersley@ed.ac.uk  
 
Why this research is important? 
Important research shows that hay fever affects up to 40% of children. Teenagers are 
particularly affected with symptoms including sneezing, itching and nasal blockage. Lots of 
teenagers are unable to play sports or concentrate on their schoolwork when their hay fever 
is bad to the extent that it can impact on their exam performance. We want to see if giving 
 
DO TEENAGERS’ HAYFEVER SYMPTOMS IMPROVE IF THEY 
ARE TREATED BY HEALTH PROFESSIONALS WITH 
SPECIFIC HAYFEVER KNOWLEDGE AND SKILLS? 
 
A Teenage Hayfever Research Study organised by the University of Edinburgh’s Allergy and 




specific hay fever training to nurses and doctors will result in improvements to their 
teenagers’ hay fever – and potentially their exam performance.   
 
Why you are being asked to take part, and what’s involved? 
We are asking you to take part because you have hay fever and are the right age. We know 
this because we are working with a nurse from your General Practice who has searched the 
medical records of all the patients registered there to identify teenagers who have hay fever.  
 
She will be inviting you to attend one special hay fever clinic this summer to discuss your 
hay fever. We will ask you to fill out one short questionnaire before you go and to fill out 
two more after you have been. Your clinic appointment should last about 15 minutes, the 
same amount of time as each questionnaire will take to complete. Taking part therefore 
requires a total of one hour of your time this summer, but it’s an hour that could end up 
improving the lives of thousands of teenagers with hay fever and potentially improving their 
exam performance.  
 
What happens next if you decide to take part? 
The first thing to do is to fill in the consent form and reply slip and send it back to Vicky 
Hammersley, the lead researcher on this study. The consent form asks for your permission 
for us to ask your doctor what medication you have been prescribed or recommended in the 
past and how often you have visited the practice during previous hay fever seasons. We 
won’t collect or record any medical information not related to your hay fever. The form will 
also ask your permission to collect your exam data from the Education Authority for one 
year. Once you have sent the form back to Vicky she’ll send you the first questionnaire or 
give you details on how to fill it in on the internet. The questionnaire asks how your hay 
fever is affecting your life right then, what symptoms you are having at the time, what 
medication you are taking to help you and how your hay fever this year compares with 
previous years. 
 
Next your nurse will invite you to attend her special hay fever clinic once in the summer. 
Here you’ll talk about your hay fever and things you could do to make you feel better and 
control your symptoms. Half of the nurses taking part will have had their special training 




Then Vicky will ask you to fill out the questionnaire twice more at particular times. She’ll be 
able to remind you to do this by texting, emailing or ringing you, whichever you choose. 
Your involvement starts in March and finishes in September. 
 
Benefits of taking part 
As well as this being a unique chance for you to take part in an important research study, we 
hope you will notice that you are better able to control your hay fever symptoms this 
summer. 
 
If you don’t want to take part 
If you don’t want to take part you don’t have to. You don’t need to give a reason and it won’t 
affect the care you get from the health service. If you do decide to take part you are still free 
to change your mind at any time, also without giving a reason.  
 
What happens to the results of the study? 
If you take part we will send you a summary of the results. Since we hope to show a link 
between specialist training and improved patient health we will also tell doctors about the 
results to help them with their work. We’ll do this by publishing our findings in a report to 
the Scottish Government’s Chief Scientist Office and in medical journals. We expect that the 
findings will be used in planning future allergy services within the NHS. 
 
Whose study is it? 
The Allergy and Respiratory Research Group at Edinburgh University’s Centre for 
Population Health Sciences is undertaking a programme of research with the aim of 
improving the delivery of care to patients with allergic disorders. This study has been funded 
the Scottish Government’s Chief Scientist Office and will run until the end of October 2009. 
It has been approved by the Lothian Research Ethics Committee. 
 
If you need more information or have questions      
Please do contact lead researcher Vicky Hammersley who will be pleased to answer any 
questions about the study, you can contact her on 0131 6503234/07969 775912 or 
vicky.hammersley@ed.ac.uk 
 
Or you can contact Dr Allison Worth (PhD): 
Research Fellow, Allergy & Respiratory Research Group, Centre for Population Health 
171 
 
Sciences: GP Section, 20 West Richmond Street, The University of Edinburgh, EH8 
9DX.Tel: 0131 6509463 or email: allison.worth@ed.ac.uk 
 
Thank you for reading this information. We hope you’ll take part in this 
important research study. 
  
Take a step toward taking part, contact Vicky Hammersley on: 
 
Direct line 0131 6503234 
Mobile 07969 775912  
Email vicky.hammersley@ed.ac.uk 
 
Or write to her at: Allergy and Respiratory Research Group, Centre for Population Health 





Participant Information Sheet- Year 2 
 
Information for teenagers  
& your parents or guardians 
The Scottish Government, University of Edinburgh, and education charity Education for 
Health are trying to find out if teenage hay fever sufferers are able to control their hay fever 
symptoms better and so improve their quality of life, if they are treated by health 
professionals who have had specific evidence based hay fever training. Or not.   
 
We needed nurses from 15 General Practices to agree to take part. We’ve sent you this 
information because one of them is a nurse from your practice. All 15 are helping us find 
100 teenagers (age 12 – 18 years) who have hay fever to also take part. If we can’t find 100 
teenagers then we can’t do the research. This sheet explains more about the research and 
what it means to take part. If you’d like even more information or have any questions which 
are not covered here, call Vicky Hammersley on 0131 6503234/07969 775912 or you can 
email her at vicky.hammersley@ed.ac.uk  
 
Why this research is important? 
Important research shows that hay fever affects up to 40% of children. Teenagers are 
particularly affected with symptoms including sneezing, itching and nasal blockage. Lots of 
teenagers are unable to play sports or concentrate on their schoolwork when their hay fever 
is bad to the extent that it can impact on their exam performance. We want to see if giving 
specific hay fever training to nurses and doctors will result in improvements to their 
teenagers’ hay fever – and potentially their exam performance.   
 
Why you are being asked to take part, and what’s involved? 
 
DO TEENAGERS’ HAYFEVER SYMPTOMS IMPROVE IF THEY 
ARE TREATED BY HEALTH PROFESSIONALS WITH SPECIFIC 
HAYFEVER KNOWLEDGE AND SKILLS? 
 
A Teenage Hayfever Research Study organised by the University of Edinburgh’s Allergy and 




We are asking you to take part because you have hay fever and are the right age. We know 
this because we are working with a nurse from your General Practice who has searched the 
medical records of all the patients registered there to identify teenagers who have hay fever.  
 
She will be inviting you to attend one special hay fever clinic this summer to discuss your 
hay fever. We will ask you to fill out one short questionnaire before you go and to fill out 
one more after you have been. Your clinic appointment should last about 15 minutes, the 
same amount of time as each questionnaire will take to complete. Taking part therefore 
requires less than one hour of your time this summer, but it’s time that could end up 
improving the lives of thousands of teenagers with hay fever and potentially improving their 
exam performance.  
 
What happens next if you decide to take part? 
The first thing to do is to fill in the consent form and reply slip and send it back to Vicky 
Hammersley, the lead researcher on this study. The consent form asks for your permission 
for us to ask your doctor what medication you have been prescribed or recommended in the 
past and how often you have visited the practice during previous hay fever seasons. We 
won’t collect or record any medical information not related to your hay fever. The form will 
also ask your permission to collect your exam data from the Education Authority for one 
year. Once you have sent the form back to Vicky she’ll send you the first questionnaire. The 
questionnaire asks how your hay fever is affecting your life right then, what symptoms you 
are having at the time, what medication you are taking to help you and how your hay fever 
this year compares with previous years. 
 
Next your nurse will invite you to attend her special hay fever clinic once in the summer. 
Here you’ll talk about your hay fever and things you could do to make you feel better and 
control your symptoms. Half of the nurses taking part will have had their special training 
before they run their clinic and half will have their training at the end of the study. 
 
Then Vicky will ask you to fill out the questionnaire once more. She’ll be able to remind you 
to do this by texting, emailing or ringing you, whichever you choose. Your involvement 
starts in March and finishes in September. 
 
Benefits of taking part 
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As well as this being a unique chance for you to take part in an important research study, we 
hope you will notice that you are better able to control your hay fever symptoms this 
summer. 
 
If you don’t want to take part 
If you don’t want to take part you don’t have to. You don’t need to give a reason and it won’t 
affect the care you get from the health service. If you do decide to take part you are still free 
to change your mind at any time, also without giving a reason.  
 
What happens to the results of the study? 
If you take part we will send you a summary of the results. Since we hope to show a link 
between specialist training and improved patient health we will also tell doctors about the 
results to help them with their work. We’ll do this by publishing our findings in a report to 
the Scottish Government’s Chief Scientist Office and in medical journals. We expect that the 
findings will be used in planning future allergy services within the NHS. 
 
Whose study is it? 
The Allergy and Respiratory Research Group at Edinburgh University’s Centre for 
Population Health Sciences is undertaking a programme of research with the aim of 
improving the delivery of care to patients with allergic disorders. This study has been funded 
the Scottish Government’s Chief Scientist Office and will run until the end of October 2009. 
It has been approved by the Lothian Research Ethics Committee. 
 
If you need more information or have questions      
Please do contact lead researcher Vicky Hammersley who will be pleased to answer any 
questions about the study, you can contact her on 0131 6503234/07969 775912 or 
vicky.hammersley@ed.ac.uk 
Or you can contact Dr Allison Worth (PhD): Research Fellow, Allergy & Respiratory 
Research Group, Centre for Population Health Sciences: GP Section, 20 West Richmond 
Street, The University of Edinburgh, EH8 9DX.Tel: 0131 6509463 or email: 
allison.worth@ed.ac.uk 
 
Thank you for reading this information. We hope you’ll take part in this 









Take a step toward taking part, contact Vicky Hammersley on: 
 
Direct line 0131 6503234 
Mobile 07969 775912  
Email vicky.hammersley@ed.ac.uk 
 
Or write to her at: Allergy and Respiratory Research Group, Centre for Population Health Sciences: 




General practice information sheet  
 
We would like your assistance with a research study. Please read the following 
information about why we are doing this research, and what it would involve for the 
practice. Please ask us if there is anything that is not clear, or if you would like more 
information. 
 
Why are we doing this research? 
Research has shown that hay fever affects up to 40% of children, with adolescents 
being particularly affected. Common symptoms are sneezing, itching and nasal 
blockage. Sometimes children find it hard to concentrate on their schoolwork or to 
play sports when they are suffering from hay fever. We want to see if training nurses 
and doctors to better help people manage their hay fever will result in improvements 
in children’s hay fever, and potentially their exam performance.  If so, this should 
result in improvements in children’s ability to undertake activities and help them to 
enjoy their lives more during the summer.  
 
What will happen in the study?  
This is a randomised controlled trial. We aim to recruit intervention and control 
practices. The intervention is in two phases, the health care professional (HCP) 
intervention is a one day short course run by Education for Health (Essential Asthma 
and Allergic rhinitis). Those HCPs in the intervention arm will be asked to attend this 
course in Spring 2009. The course is free of charge, and backfill costs will be 
covered where required. The next phase of the intervention is for HCPs in the 
intervention and control practices to see patients aged 12-18 years with a history of 
hay fever in a clinic in early Summer 2009. This will be to discuss their hay fever 
and ways to better help them to control their symptoms.  
ADOLESCENT HAYFEVER AND QUALITY OF LIFE 
A randomised trial organised by the University of Edinburgh’s Allergy and 





Practice staff will be asked to identify eligible children and young adults with hay 
fever from the medical records, with the help of a search strategy, mail out 
invitations to those eligible, and send reminders after two weeks. Those children who 
consent to take part will be required to make a clinic appointment, and the 
researcher, Vicky Hammersley, will liaise with the practice to ensure these 
appointments are made. Children who agree to take part in the study will be required 
to complete three sets of questionnaires; however this will be facilitated by the 
researcher. 
 
Why has my practice been identified? 
We are looking for assistance from practices in the Lothian. 
 
What are the search criteria? 
Using Read code clinical terms v2 the following searches will be used to identify 
eligible patients: 
 Patients aged 12-18 years currently registered, 
 Patients with a recorded diagnosis of hay fever (H17..), 
 and/or evidence of use of hay fever medication: oral antihistamines and 
topical steroids (c8... and c6…). 
 
What are the exclusion criteria? 
Patients will be excluded if they are unable to give consent or are taking part in any 
other clinical trials involving treatments for allergic rhinitis. 
 
Are any medicines or treatment involved in this study? 
We are not testing any new medicines in this study. 
 
What are the possible disadvantages and risks of taking part? 
The HCPs in the control practices will not receive the allergy training for the 
duration of the trial, they will continue to provide the routine clinical care for their 
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patients. The control practices will be invited to attend the Essential Asthma and 
Allergic Rhinitis one day course when the trial is complete. 
 
What are the possible benefits of taking part? 
It is hoped that there will be improvement in the control of hay fever symptoms in 
participants as a result of taking part in this study.  
 
What if there is a problem? 
Please contact Vicky Hammersley (contact details below) if you have any complaints 
about this study, and they will be addressed by the research team. 
 
Who is carrying out this study? 
The Allergy and Respiratory Research Group at Edinburgh University’s Division of 
Community Health Sciences is undertaking a programme of research with the aim of 
improving the delivery of care to patients with allergic disorders. This study has been 
funded the Scottish Government’s Chief Scientist Office and will run until the end of 
October 2009. 
 
What will happen to the results of the study? 
We will publish the findings in a report to the Scottish Government’s Chief Scientist 
Office and in medical journals. We expect that the findings will be used in planning 
future allergy services within the NHS. 
 
What if I have some questions about the study?      
Vicky Hammersley will be pleased to answer any questions about the study, you can 
contact her on 0131 6503234/07969 775912 or vicky.hammersley@ed.ac.uk 
 
Or you can contact Dr Allison Worth (PhD): 
Research Fellow, Allergy & Respiratory Research Group, Division of Community 





Thank you very much for taking the time to read this information. 
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Appendix 5: Consent forms 
Consent form for 12-15 years 
MANAGING YOUR HAY FEVER  
A study organised by the University of Edinburgh’s Allergy 
and Respiratory Research Group.  
 
Name (please print)       DoB      
 
Please initial box 
1. I have read and understood the information sheet for the above 
study and have had the opportunity to ask questions. 
 
2. I understand that it is OK to stop taking part at any time.  
3. I understand that the study will involve filling in questionnaires 
about my hay fever 
 
4. I understand that if the results of the study are published it will 
not be possible to identify me. 
 
5. I understand that if I do decide to withdraw from the study, the 
researchers cannot use the information already collected up to that 
point without my consent. 
 
6. I understand that by giving my preferred telephone number 
and/or email address to the researchers I am agreeing to be 
contacted by them. 
 
7. I am happy for Vicky to tell my GP that I am taking part in this 





8. I am happy for Vicky to obtain my assessment/exam results 
from the Education Authority. 
 




Signature Date  
 








Consent form for 16-18 years 
MANAGING YOUR HAY FEVER  
A study organised by the University of Edinburgh’s Allergy 
and Respiratory Research Group 
 
Name (please print)       DoB      
Delete as appropriate 
I confirm that I have read and understand the information leaflet for the above study Yes/No 
I understand that if I have any questions about the study I can contact Vicky  Yes/No 
I understand that the study will involve filling in questionnaires about my hay fever Yes/No 
I understand that all the information about me recorded for this project will be completely 
anonymous. If the results of the study are published it will not be possible to identify me. 
Yes/No 
I understand that it is up to me whether I take part, and that I am free to withdraw at any time, 
without giving any reason and without my medical care or legal rights being affected 
Yes/No 
I understand that if I do decide to withdraw from the study, the researchers cannot use the 
information already collected up to that point without my consent. 
Yes/No 
I understand that by giving my preferred telephone number and email address to the researchers I 
am agreeing to be contacted by them. 
Yes/No 
I am happy for the Vicky to tell my GP that I am taking part in this study and get information 
about my hay fever. 
Yes/No 
I am happy for Vicky to obtain my assessment/exam results from the Education Authority. Yes/No 









Please return this signed consent form to Vicky Hammersley in the envelope 
provided. 
Thank you for helping us with this study. 
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Once you have read the information sheet provided please answer the following 
questions.  
           
        Delete as appropriate 
We have read and understood the information provided.  Yes/No 
 















      
Practice Manager Name 
 
 
           
 
Signature of practice representative  Date 
 
ADOLESCENT HAYFEVER AND QUALITY 
OF LIFE 
A randomised trial organised by the University of Edinburgh’s 
Allergy and Respiratory Research Group  
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Appendix 6: Patient data collection form 
Please ask your parents/guardians to help you complete these questions 
 
Date today:    /    /    
 
1. Please give your full name  
 
2. Please give you date of birth  
 
3. Are you male or female?  
 
4. What year are you in at school?  
 
5. What was your last school exam/assessment?  
 
6. What is your next school exam/assessment?  
 
7. How old where you when you first got 
hayfever? 
 
8. Which month of the year do your symptoms 
start? 
 
9. What medicines do you usually get from your 
doctor? 
 
10. What medicines do you usually buy from the 
chemist? 
 
11. Do you have regular access to the internet? 
 
 
12. Please list your contact details and tick 




 Home phone: 
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 Email address: 
 
 













Appendix 7: Description of the derivation of the two 
different Indices of Multiple Deprivation across English and 
Scottish sites 
 
The Index of Multiple Deprivation 2004(Noble et al. 2004) (IMD 2004) is a measure 
of multiple deprivation at a small level and is based on dimensions of deprivation 
which can measured separately. The IMD 2004 contains seven domains of 
deprivation: income, employment, health and disability, skills and training, barriers 
to housing and services, living environment and crime. The IMD 2004 score was 
obtained for each cluster (general practice) by using linked files which first 
associated each clusters complete post code with a Super Output Area (SOA) and 
then the SOA with the IMD. General practice IMD 2004 scores for the practices in 
England were used as a proxy measure for the population of patients registered, as 
patient level IMD 2004 scores were not available. 
 
The Scottish Index of Multiple Deprivation(The Scottish Government 2006) (SIMD) 
is the Scottish Governments official measure for identifying areas of deprivation in 
Scotland and is based on 37 indicators across seven domains: current income, 
employment, health, education, housing, geographic access to services, and crime. 
Different areas of Scotland are assigned to one of five quintiles according to their 
SIMD score, quintiles are ranked by deprivation with Quintile 1 containing the 20% 
most deprived datazones in Scotland and Quintile 5 containing the 20% least 
deprived datazones in Scotland. The weighted mean of quintiles 1-5 was calculated 
for each cluster based on the number of patients matched to each quintile for the 





Appendix 8: British Society of Allergy and Clinical 

























Appendix 10: Visual Analogue Scale 
 
Managing your hay fever study: Symptom Score questionnaire 
Name       
 
Study Number     
 
Date       
 
 
“How has your hay fever been this week?” 
 
 
No symptoms             Very bad symptoms 
 
 




Appendix 11: Description of extension to the second year 
of recruitment 
The protocol for this trial stated a recruitment period of one year, relating to one 
hay fever season, however despite recruiting enough adolescents into the trial, the 
number of complete primary outcome data sets was not enough to achieve the 
required power. The power calculation in the protocol was based on requiring 80% 
power to detect as significant at the 5% level a mean intervention effect of 0.5 on 
the RQLQ scale, assuming a standard deviation of 1.2. This gave an unadjusted 
sample size of 180, which inflated to 220 assuming an ICC of 0.02 and a mean 
cluster size of 10 (i.e. a design effect of 1.22, giving 22 clusters of size 10). At the 
end of data collection, final RQLQ(S) data were collected from 180 patients in 23 
clusters, however only 156 patients in 21 clusters returned both baseline and final 
RQLQ(S). The implications of this loss of follow-up data on the power of the study 
are shown in the table below.  
 
Table: Power calculations for varying ICCs to detect the required effect size of 
0.5 
 
ICC No. required 
to detect 




existing nos. with 
80% power 
Power for 0.5 effect size 
with existing nos. 
0.01 201 0.53 0.76 
0.02 220 0.55 0.72 
0.03 238 0.58 0.68 
 
The table shows that based on 180 subjects with a final RQLQ(S) and an ICC of 
0.02 (the original estimate) the power is reduced to 72%, or that we required 220 
patients to detect the required effect size. This coincidentally is the same as the 
original estimate, but the loss of power due the variation in cluster size from the 21 
clusters is offset by a reduction in the design effect from having more clusters with 
fewer subjects in them (Eldridge, Ashby et al. 2006).  
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Appendix 12: Terms of reference for Trial Steering 
Committee 
 
TRIAL STEERING COMMITTEE (TSC) 
 
Cluster randomised controlled trial of an educational intervention for 
healthcare professionals for the management of school-age children with hay 
fever. 
 
TERMS OF REFERENCE  
 
 Overall supervision of the trial 
 Approval of the final version of the protocol 
 Assuring patient safety and ethics 
 Monitoring progress of the research to its overall objectives 
 Monitoring adherence to the protocol 
 Approving changes to the protocol 
 Monitoring the progress of the trial 
 Considering any new information that might be relevant to the trial and its 
continuation 
 Monitoring the dissemination of results 




MEMBERSHIP AND AFFILIATION OF THE TSC 
 
Chair:  
Professor Tony Avery, Professor in Primary Care, School of Community Health 
Sciences, University of Nottingham. 
 
Independent Members: 
Dr Sarah Rodgers, Lecturer in Pharmacy, School of Pharmacy, University of 
Nottingham. 
Dr Glenis Scadding, Consultant Physician in Allergy and Rhinology, Royal 
National Throat, Nose and Ear Hospital, London. 
Dr Sarah Armstrong, Senior Lecturer in Medical Statistics, School of Community 
Health Sciences, University of Nottingham. 
 
Project Team 
Victoria Hammersley, CSO Research Fellow/PhD student, Division of Community 
Health Sciences, University of Edinburgh. 
 
Professor Aziz Sheikh, Professor of Primary Care Research & Development 




Dr Samantha Walker, Director of Research, Education for Health, Warwick & 
Senior Lecturer (hon.), University of Edinburgh. 
 




Appendix 13: Consort Checklist 
 
 PAPER SECTION 
and topic 
Item  Descriptor Reported on 
Page No.  
TITLE & 
ABSTRACT 
1* How participants were allocated to interventions (e.g., “random 
allocation”, “randomised”, or “randomly assigned”), specifying 




2* Scientific background and explanation of rationale, including 




3* Eligibility criteria for participants and clusters and the settings 
and locations where the data were collected.   
58-63 
Interventions 4* Precise details of the interventions intended for each group, 
whether they pertain to the individual level, the cluster level or 
both, and how and when they were actually administered. 
65-69 
Objectives 5* Specific objectives and hypotheses, and whether they pertain to 
the individual level, the cluster level or both.  
47 
Outcomes 6* Report clearly defined primary and secondary outcome 
measures, whether they pertain to the individual level, the 
cluster level or both, and, when applicable, any methods used to 
enhance the quality of measurements (e.g., multiple 
observations, training of assessors). 
 
70 
Sample size 7* How total sample size was determined (including method of 
calculation, number of clusters, cluster size, a coefficient of 
intracluster correlation (ICC or k), and an indication of its 
uncertainty) and, when applicable, explanation of any interim 







Method used to generate the random allocation sequence, 





9* Method used to implement the random allocation sequence, 
specifying that allocation was based on clusters rather than 
individuals and clarifying whether the sequence was concealed 
until interventions were assigned.  
 
Implementation 10 Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups. 
 
Blinding (Masking) 11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were blinded to 
group assignment. If done, how the success of blinding was 
evaluated. 
63 
Statistical methods 12* Statistical methods used to compare groups for primary 
outcome(s) indicating how clustering was taken into account; 








Flow of clusters and individual participants through each stage 
(a diagram is strongly recommended). Specifically, for each 
group report the numbers of clusters and participants randomly 
assigned, receiving intended treatment, completing the study 
protocol, and analyzed for the primary outcome. Describe 
protocol deviations from study as planned, together with 
reasons. 
80 
Recruitment 14 Dates defining the periods of recruitment and follow-up. 71 
Baseline data 15* Baseline information for each group for the individual and 
cluster levels as applicable 
77 
Numbers analyzed 16* Number of clusters and participants (denominator) in each 
group included in each analysis and whether the analysis was by 




feasible (e.g., 10/20, not 50%).  
Outcomes and 
Estimation 
17* For each primary and secondary outcome, a summary of results 
for each group measures for the individual or cluster level as 
applicable, and the estimated effect size and its precision (e.g., 
95% confidence interval) and a coefficient of  intracluster 
correlation (ICC or k) for each primary outcome.  
84 
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, 
including subgroup analyses and adjusted analyses, indicating 
those pre-specified and those exploratory. 
89 








Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision and the 
dangers associated with multiplicity of analyses and outcomes. 
100 
Generalisability 21* Generalisability (external validity) to individuals and/or clusters 
(as relevant) of the trial findings. 
115 
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Appendix 15: Detailed costings for the trial 
 
Scottish practice costs  
Practice activity Practitioner involved Average time / cost per item 
Hourly (or per item) 
rate (£) 
Practice time for study 
/ nos items 
Total amount 
Discuss study, read protocol, inform 
practice team GP 1h 54 1 54 
 
Nurse 1h 23 1 23 
 
Practice manager 1h 20 1 20 
Facilitate visit (from Study Manager) Practice manager 1h 20 1 20 
Search practice database Practice manager 2h 20 2 40 
Screen list of patients GP 
1h up to 200 patients; 2h up to 
400 patients  54 1 54 
Mailing to patients Receptionist 
2h up to 100 patients; 30 min 
extra per 100 11 2 22 
Appts with 15 patients - approx 15 
minutes per patient Nurse 1h 23 4 92 
Allocating appointments Receptionist 2h per 100 patients 11 1 11 
Answer patient queries GP 1h 54 1 54 
Postage 
 









10p per invitation 0.1 
 
0.00 
Use of room 
 
per hour 10 
 
0 
      
    
Per practice (£) 390.00 
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English practice costs 
 
Practice activity Practitioner involved Average time / cost per item 
Hourly (or per item) 
rate (£) 
Practice time for study 
/ nos items 
Total amount 
Discuss study, read protocol, 
inform practice team GP 1h 77.18 1 77.18 
 
Nurse 1h 27.56 1 27.56 
 
Practice manager 1h 27.56 1 27.56 
Facilitate visit (from Study 
Manager) Practice manager 1h 27.56 1 27.56 
Search practice database Practice manager 2h 27.56 2 55.12 
Screen list of patients GP 
1h up to 200 patients; 2h up to 
400 patients  77.18 1 77.18 
Mailing to patients Receptionist 
2h up to 100 patients; 30 min 
extra per 100 19.95 2 39.9 
Appts with 10 patients - approx 15 
minutes per patient Nurse 0.25 per patient 27.56 4 110.24 
Allocating appointments Receptionist 2h per 100 patients 19.95 1 19.95 
Answer patient queries GP 1h 77.18 1 77.18 
Postage 
 









10p per invitation 0.1 
 
0.00 
Use of room 
 
per hour 15 
 
0 
      
    
Per practice (£) 539.43 
 
